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Abstract
CD38 is a type II transmembrane glycoprotein that is associated with poor 
prognosis in chronic lymphocytic leukaemia (CLL), but to-date there is no 
biological rationale for this association. This study was designed to investigate 
the role of CD38 within CLL and answer some o f the controversial questions 
relating to CD38 in this leukaemia.
Since the identification of CD38 as a prognostic marker in CLL there has been 
great debate about whether CD38 is a proxy marker for Vh gene mutation 
status. In addition, there has also been controversy over the most appropriate 
percentage threshold to use in order to categorise a patient as CD38+. In this 
study I found a strong correlation between CD38 and Vh gene mutation status 
but the degree o f discordance between these parameters precludes CD38 from 
being used a reliable surrogate marker for Vh gene mutation status. Previous 
studies have listed three different percentage thresholds for the classification 
of patients with CD38 expression; 7%, 20% and 30%. In this study I evaluated 
all three threshold levels; 20% was the most prognostically significant 
threshold. Another question relating to CD38 expression is whether it remains 
stable over time. Longitudinal analyses showed that CD38 expression remains 
constant over time and after treatment. Although CD38 expression was 
independently prognostic, the combination of CD38 expression and Vh gene 
mutation status for each patient provided a more robust measure o f the 
patient’s clinical course.
In the next part o f this study I employed microarray analysis to compare 
CD38+ and CD38' cells from the same patient purified by high speed cell 
sorting. CD38+ CLL cells demonstrated a unique gene expression profile when 
compared to their CD38' counter-parts with 61 genes found to be consistently 
statistically different. Six genes were investigated further, VEGF, IL-lp, 
CXCL2, CCR3, ZAP-70 and Akt. Using flow cytometry and Western blotting 
techniques it was confirmed that these proteins were expressed at significantly 
higher levels in CD38+ sub-populations when compared to the CD38‘ sub­
Abstract
populations. CD38+ and CD38' cells from the same patient showed similar 
drug sensitivity to fludarabine in the majority o f samples tested. However, 
samples from five patients who had received the most prior treatment showed 
greater resistance to drug therapy in their CD38+ CLL cells. The apoptotic 
proteins Bcl-2, Bax and Mcl-1 were up-regulated in the CD38+ cells.
The combination o f CD38 expression data with other prognostic factors such 
as Vh gene mutational status and ZAP-70 expression will be beneficial in 
determining the prognosis of the patients and the course o f treatment. Also 
determining the role o f CD38 within CLL cells could lead to new therapeutic 
targets.
xiv
Chapter 1
Chapter 1: Introduction
1.1 Haemopoiesis
Haemopoiesis is the process by which blood cells are produced and it 
mainly occurs in the bone marrow of the central skeleton and proximal
ends of long bones. A stem cell found in the bone marrow can self
replicate, proliferate and differentiate (Mayani, Alvarado-Moreno, & 
Flores-Guzman 2003). After many divisions in the bone marrow, mature 
cells are formed which are then released into the peripheral blood.
The haemopoietic (pluripotent) stem cell gives rise to at least 10 different 
functional cell types; neutrophils, monocytes/macrophages, basophils, 
eosinophils, erythrocytes, platelets, mast cells, dendritic cells, B- and T- 
lymphocytes (Mehts & Hoffbrand 2000). Around 2xlOn erythrocytes and 
lxlO10 white blood cells must be replaced everyday to maintain
haemopoiesis (Bellantuono 2004) (see Figure 1.1). Haemopoiesis is
regulated by many growth factors, cytokines and interleukins. These are 
usually produced by stromal cells, T-lymphocytes, the liver and the kidney. 
They affect primitive cells, cells that have committed to a particular lineage 
and later on the function of mature cells. The growth factor/ cytokine/ 
interleukin binds to the receptor on the cell surface and initiates a 
signalling cascade that activates transcription factors which in turn activate 
or inhibit gene transcription. This process can lead to activation, 
replication, proliferation, differentiation or cell survival.
1
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Figure 1.1: Normal haemopoiesis. The production o f different cell lineages from 
a pleuripotent stem cell.(Walsby 2004).
Many growth factors are involved during haemopoiesis including 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), monocyte colony stimulating factor 
(M-CSF), Interleukin (IL)-l, IL-3, IL-4, IL-6 and IL-8 (Ribatti et al. 2001). 
IL-1 and TNF act on stromal cells and stimulate the production of GM-
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CSF, G-CSF, M-CSF and IL-6. Stem cell factor acts on pleuripotent cells. 
IL-3, IL-4, IL-6 and GM-CSF all act on multi-potent cells. The growth 
factors that act on committed progenitor cells are G-CSF, M-CSF, IL-5 
(eosinophils CSF), erythropoietin and thrombopoietin (Mehts & Hoffbrand 
2000). Haemopoietic stem cells (HSC) give rise to multi-potent 
progenitors (MPP), and from MPP differentiation common myeloid 
precursors (CMP) and common lymphoid precursors (CLP) are produced. 
B-lymphocytes, T-lymphocytes and natural killer cells are thought to be 
produced from these CLP’s.
1.2 Lymphocytes
Flaemopoietic stem cells give rise to lymphocytes which are important 
members of the immune response system. There are two types of 
lymphocytes, B-lymphocytes and T-lymphocytes with the majority of the 
peripheral blood lymphocytes being T-lymphocytes (approximately 70%). 
B-lymphocytes mature mainly in the bone marrow whereas T-lymphocyte 
maturation occurs mainly in the thymus, but lymph nodes, liver and spleen 
also play an important part. B-cells mediate humoral (antibody-mediated) 
immunity and T-cells are involved in cell mediated immunity.
1.3 Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in 
the Western world (Dighiero 2005), predominantly affecting individuals
3
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over the age of forty (median age of diagnosis is 68 years) with a higher 
incidence in men than women in approximately a 2:1 ratio (Montserrat & 
Rozman 1994). It is characterised by the over expression of mature-looking 
CD19+/CD5+ B-lymphocytes, which also express the pan B-cell markers 
CD20 and CD23 (Dighiero 2005). These cells have weak expression of 
surface immunoglobulins such as IgM and IgD and have weak expression 
of CD79p (part of the B-cell receptor (BCR)) (Dighiero 2005). Low 
expression of the BCR leads to reduced tyrosine kinase activity, which in 
turn leads to reduced calcium mobilisation and therefore reduced 
responsiveness of the cells when signalling through this receptor. 
Peripheral blood CLL cells are mainly found in Go/Gi of the cell cycle, but 
the presence of cyclins D and E within these cells suggest that the cells are 
not truly quiescent but are more likely in early Gi (Decker et al. 
2003;Decker et al. 2004). The clonal expansion of B-lymphocytes in CLL 
is due, in part, to dysregulation of survival pathways which results in failed 
apoptosis rather than a high proliferation rate (Shanafelt, Geyer, & Kay
2004). Messmer et al ( 2005) found that B-CLL cells have quite a high 
birth rate and so suggests that the build up of CLL cells is due to increased 
proliferation as well as failed apoptosis. The clinical course of CLL is 
variable, ranging from a mild disease, with very few symptoms, to an 
aggressive disease with poor clinical outcome. Approximately a third of 
CLL patients have an indolent disease and never receive treatment (median 
survival 12 years), another one third initially have an indolent disease that 
after a period develops into progressive disease (median survival 5 years), 
and the final third have an aggressive and progressive disease from
4
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diagnosis (median survival 2 years) (Montserrat & Rozman 
1994;Shanafelt, Geyer, & Kay 2004).
1.4 Staging
There are two main staging systems within CLL which are summarised in 
Table 1. These staging systems were devised as CLL has a variable clinical 
course and before the introduction of these systems there was no way of 
determining which patients would have a favourable clinical course and 
which patients would have poor clinical outcome. Both the Binet and Rai 
system provided a staging system separating the patients into a good,
intermediate and poor clinical outcome.
Binet Rai
Stage A <3 enlarged areas*, 
haemoglobin >10g/dL and platelets 
>100,000/mm3
Stage 0 Peripheral and bone marrow 
lymphocytosis without lymph node 
enlargement or splenomegaly
Stage I Stage 0 with lymph node 
enlargement but without 
splenomegaly
Stage B >3 enlarged areas, 
haemoglobin >10g/dL and platelets 
>100,000/mm3
Stage II Stage 0 without lymph 
node enlargement but with palpable 
splenomegaly
Stage III Stage 0 with lymph node 
enlargement and palpable 
splenomegaly
Stage C any number of enlarged 
areas, haemoglobin <10g/dL and/or 
platelets <100,000/mm3
Stage IV Stage 0 with either fairly 
severe anaemia (haemoglobin < lOg) 
or thrombocytopenia (platelets < 
100,000/mm3)
Table 1: Binet and Rai staging systems for CLL (Binet et al. 1981;Rai et al. 
1975)
* each of cervical, axillary, inguinal areas (whether unilateral or bilateral), spleen 
and liver count as one area: therefore the number of enlarged areas can take any 
value between 0 and 5.
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Throughout this investigation, the Binet system was used. When comparing 
the two systems, it is considered that Binet stage A is equivalent to Rai 
stage 0, Binet stage B is equivalent to Rai stage I/II and Binet stage C is 
equivalent to Rai stage III/IV.
1.5 Clinical symptoms and diagnosis
Some patients display fatigue, fever, night sweats, weight loss (>10% body 
weight), repeated infections, autoimmune haemolytic anaemia, 
splenomegaly, hepatomegaly, lymphadenopathy or extra nodal infiltrates, 
but a high percentage of the patients are asymptomatic (Rai 1996). The 
disease is usually found within the asymptomatic patients after routine 
blood tests for unrelated matters (Montserrat & Rozman 1994). Diagnosis 
of CLL usually occurs when a patients displays a persistent absolute 
lymphocyte count (ALC) >5.0 x 109/L (Montserrat & Rozman 1994). This 
is followed by immunophenotyping using flow cytometry and sometimes 
cytogenetic evaluation, usually by fluorescence in situ hybridization 
(FISH), which help to distinguish CLL from other similar B-cell 
malignancies (Kalil & Cheson 1999).
1.6 Markers of Disease
The Binet and Rai staging systems were the first way of segregating 
patients into different prognostic groups. Today there are many different 
markers used which are prognostic. The most commonly used are
6
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lymphocyte doubling time (LDT), (32 microglobulin, serum thymidine 
kinase, soluble CD23, cytogenetics, Vh gene mutation status, CD38 
expression and ZAP-70 expression.
1.6.1 Lymphocyte Doubling Time
Lymphocyte doubling time (LDT) is a clinical measurement of the time in 
months it takes for the patients’ lymphocyte count to double. It is split into 
two groups; patients with a LDT >12 months and patients with a LDT <12 
months. The patients with a LDT <12 months have a more aggressive and 
progressive disease and shorter survival than the patients with a LDT >12 
months (Shanafelt & Call 2004). It has been reported that CLL patients 
with a LDT >12 had a median survival of 118 months whereas the patients 
with a LDT <12 months had a median survival of 61 months (Shanafelt, 
Geyer, & Kay 2004).
1.6.2 (32 microglobulin
One marker that correlates with Binet stage is (32 microglobulin (B2M). 
B2M is a protein that is associated with class I major histocompatibility 
complex (Montillo et al. 2005). It is thought that high B2M, which is 
detected in the serum, is prognostic in CLL as it has been associated with 
shorter survival (Shanafelt, Geyer, & Kay 2004). Wierda et al ( 2007) 
included B2M in a nomogram for prognosis. Out of the six variables that 
were used in the nomogram, age and B2M gave the greatest contribution to
7
Chapter 1
the test. This nomogram helps to identify the patients who are high risk and 
should receive treatment (Wierda et al. 2007).
1.6.3 Thymidine kinase
Thymidine kinase (TK) is an enzyme involved in the complementary 
alternative salvage pathway of DNA synthesis (Shanafelt, Geyer, & Kay
2004). It converts deoxythymidine to deoxythymidine monophosphate. TK 
levels have been associated with poor prognosis in CLL patients, and give 
valuable prognostic information in regard to response to therapy. High TK 
levels have been shown by Matthews et al ( 2006) to correlate with other 
prognostic markers such as Vh gene mutation status and CD38 expression. 
The dispute over the most appropriate cut-off value and the fact that until 
recently the assay required the use of radio-isotopes has limited the use of 
TK as a prognostic marker in the clinic.
1.6.4 Soluble CD23
CD23 is surface molecule that is found on CLL B-cells (Montillo et al
2005). Soluble version of CD23 (sCD23) has been shown to be a marker of 
poor prognosis in CLL with an association with shorter progression-free 
survival and overall survival (Molica 1997).
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1.6.5 Cytogenetics
There are many cytogenetic abnormalities that are associated with CLL. 
The most common is a deletion at 13ql4 which is usually associated with 
patients that have good prognosis (Thornton et al. 2004). These patients 
have the same prognosis as those patients who have no cytogenetic 
abnormalities. In contrast, patients that express a 17p deletion (17p-) or an 
l lq  deletion (11 q-) have a poor clinical outcome (Dighiero 2003). A 17p 
deletion often involves deletion or mutation of the p53 gene and an 1 lq 
deletion usually disrupts the ATM gene (Mehes 2005). Mutations of the 
p53 gene occurs in 10% - 15% of CLL patients but Pettitt et al ( 2001) 
stated that dysfunction of the p53 protein can occur in CLL through 
alternative mechanisms. One example of this is some patients have a extra 
copy of chromosome 12 which codes for the p53 inhibitory protein, 
MDM2. Also inactivation of ATM gene is another cause of p53 
dysfunction in CLL patients. Patients that express trisomy 12 or 6 q deletion 
(6 q-) have an intermediate prognosis as they have a better clinical outcome 
than patients with 17p or l lq  deletion, but they have shorter overall 
survival than those with 13ql4 deletion or no cytogenetic abnormalities 
(Cuneo et al. 2004;Dohner et al. 1995). Patients with p53 mutations have 
poor clinical outcome and drug resistance (Carter et al. 2004).
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1 .6 . 6  Vh genes
There is a three step process for the maturation of a B-cell: the process 
begins with a naive B-cell; one that has not yet encountered antigen. The 
second step occurs mainly in the germinal centre. After encountering 
antigen, the B-cell travels to the germinal centre where rearrangement or 
somatic hypermutation occurs in the heavy region of their immunoglobulin 
genes. The B-lymphocytes are then termed “mutated”. During somatic 
hypermutation, individual nucleotides within the variable (V) region, 
diversity (D) region or joining (J) region are replaced with alternatives 
nucleotides in order to increase antibody diversity (Goldsby, Kindt, & 
Osbourne 2000). The third step is termed the post-mutational stage. A 
memory B-cell leaves the germinal centre and can either join the 
circulating B-cells, go to the antigen draining site (e.g. marginal zone of the 
spleen), or can differentiate into a plasma cell (Stevenson et al. 1998).
On closer inspection of CLL, it was found that the disease could be sub­
divided into two prognostic groups, dependent on the mutational status of 
their cells’ immunoglobulin heavy chain variable genes (Vh genes). If there 
is a difference of 2 % or less from the closest germ line sequence, then the 
cells are said to be “unmutated”. The cells are classed as “mutated” when 
there is a difference of >2% from the closest germ line sequence (Oscier et 
al. 2002). There is controversy in the literature over this 98% threshold 
level, as some studies have shown that a 97%, 96% or 95% (Krober et al. 
2002;Wiestner et al. 2003) cut-off level are better representatives of the
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patients’ clinical outcome but usually the 98% threshold level is used 
clinically. It was generally believed that the mutated cells are more mature 
cells that have transited the germinal centre, whereas the unmutated 
lymphocytes, although they have experience antigen and therefore are not 
naive, it is thought that they have not transited the germinal centre, so they 
are not as mature as mutated CLL cells (Dighiero 2003). It is now believed 
that the unmutated cells do actually transit the germinal centre but for an 
unknown reason, do not undergo somatic hypermutation and hence fail to 
rearrange their Vh genes (Stevenson & Caligaris-Cappio 2004). Patients 
with mutated Vh genes have a better prognosis and longer time to first 
treatment. In contrast, patients with the unmutated VH genes have a more 
progressive disease and poorer clinical outcome (Hamblin et al. 1999;Lin 
et al. 2002;Vilpo et al. 2003).
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Figure 1.2 Kaplan-Meier curve showing the overall survival for patients with 
either unmutated VH gene mutation status or mutated VH gene mutation 
status (Hamblin, Davis, Gardiner, Oscier, & Stevenson 1999)
Patients with unmutated VH genes had a shorter overall survival than the patients 
with mutated VH genes.
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During B-cell maturation, rearrangement of the variable region occurs, 
starting with the heavy chain variable region, then the light chain variable 
region. With the heavy chain region, a Dh gene segment joins to a Jh 
segment. This resulting DhJh segment then joins with a Vh segment to 
generate a VhDhJh segment that encodes the entire variable region 
(Goldsby, Kindt, & Osbourne 2000). CLL patients appear to use a limited 
repertoire of Vh gene segments. The most common ones are Vh4-34, VhI- 
69 and Vh3-21. The patients can be sub-divided depending on what Vh 
segment usage they display (how the gene segments are rearranged). The 
most commonly displayed VH gene usage is Vh4-34 and these patients 
usually have a mutated VH genes and a good prognosis. In contrast, patients 
that use Vh1-69 usually have unmutated VH genes and have aggressive 
disease with short overall survival (Kienle et al. 2006). Although patients 
with unmutated VH genes usually have a poorer prognosis than patients with 
mutated VH gene regardless of their VH gene segment usage, an exception to this 
rule are those patients that display Vh3-21 segment usage. These patients 
usually have mutated VH genes but display a clinical course similar to those 
patients that have unmutated Vh genes (Fait et al. 2005;Ghia et al. 2005).
The process by which the mutational status of the patient is deduced is 
relatively complex and expensive and many laboratories are not equipped 
to carry out the technique. As a consequence, there has been considerable 
interest in identifying a surrogate marker for Vh gene status. A few 
suggestions have been made including CD38 expression and ZAP-70 
expression.
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1.6.7 CD38
CD38 (also known as T10) (Ibrahim et al. 2001) is a 45kDa type II 
transmembrane marker that is involved in cell signalling (Morabito et al.
2 0 0 1 ), and has also been linked to proliferation within normal lymphocytes 
(Zupo et al. 1994). The CD38 gene is found on chromosome 4pl5 
(Malavasi et al. 1994) and can be expressed in B- and T-lymphocytes, 
plasma cells, macrophages and erythrocytes (Sun et al. 2006). It is a 
multifunctional cyclase that is thought to allow extracellular adenosine 
diphosphate ribosyl cyclase (cADPr) to traverse the cell membrane and 
activate intracellular ryanodine receptors that release Ca into the 
cytoplasm from endoplasmic reticular stores (Sun et al 2006). cADPR is 
involved in signalling and has the ability to control calcium levels (Deaglio 
et al. 2006). The ligand for CD38 is CD31 (also known as platelet 
endothelial cells adhesion molecule-1 (PECAM-1)) (Ibrahim et al 
2001;Morabito et al 2001) a 130kDa molecule that is a member of the 
immunoglobulin super family and is involved in the modulation of 
leukocyte adhesion to the vessels (Deaglio et al 2006). It has been shown 
that CD31/CD38 interactions control an active signalling pathway in 
lymphocytes (Deaglio et al. 2003). It is thought that CD38 is located in the 
plasma membrane in close proximity to the BCR and TCR (Deaglio et al 
2006).
As well as proliferation, CD38 has been associated with apoptosis, 
differentiation, T-lymphocyte signalling, neutrophil migration, insulin
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secretion and neurotransmission depending on the cell type (Lande et al. 
2002;Zupo et al 1994). It has also been shown that CD38 is involved in 
disease pathophysiology (Sun et al 2006). Up-regulation of CD38 on 
different T-lymphocyte sub-sets plays a role in the ability of HIV therapies 
to reconstitute CD4+ cells (Sun et al 2006). Another function of CD38 is 
that it can induce phosphorylation of CD 19 (there is thought to be a 
physical association between CD38 and CD 19) and this prevents apoptosis 
through up-regulation of the Bcl-2 family proteins (Deaglio et al 
2006;Pittner et al. 2005). It has also been shown that CD38 signalling 
involves c-Cbl which then associates with the p85 sub-unit of PI3K which 
activates the PI3K pathway (Shubinsky & Schlesinger 1997). The tyrosine 
phosphorylation of CD 19 by CD38 is also associated with Lyn and it is
I
thought that Ca flux due to CD38 signalling can only occur when CD 19 
is activated (Deaglio et al 2006).
CD38 has been shown to be prognostic in CLL (Ghia et al. 2003;Hamblin 
et al. 2002). There are essentially three types of CD38 expression in CLL 
cells; entirely positive, entirely negative, or bimodal expression, where the 
patient has distinct populations of both CD38+ and CD38' cells (Ghia, 
Guida, Stella, Gottardi, Geuna, Strola, Scielzo, & Caligaris-Cappio 2003). 
There is much controversy over the level at which patients that express 
CD38 are classed as positive (Damle et al. 1999;Ibrahim et al 2001;Krober 
et al 2002). Suggested “cut-off’ levels from previous studies are 7%, 20% 
and 30% (Damle et al 1999;Ibrahim et al 2001;Thomton et al 2004). 
However, Ghia et al (Ghia et al 2003) found that any presence of CD38+
14
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cells, no matter how small in number, is indicative of poor overall survival. 
There is also great debate whether the expression levels of CD38 remain 
constant throughout the course of the disease, or whether the levels 
fluctuate with disease progression and/or after treatment (Hamblin et al 
2002;Ibrahim et al 2001). In this regard, patients who express CD38 appear 
to respond poorly to treatment (Pittner et al 2005).
1.6.8 ZAP-70
Zeta associated protein-70 (ZAP-70) is a member of the protein tyrosine 
kinase family (PTK) (Hus et al. 2006). It is found in T-lymphocytes and 
natural killer (NK) cells and is a member of the signalling pathway that is 
activated by the T-cell receptor (TCR) (Crespo et al. 2003;Schroers et al. 
2005). ZAP-70 is generally considered to be the T-cell equivalent of the 
BCR-associated protein Syk, which also belongs to the PTK family and is 
involved in B-lymphocyte signalling (Nolz et al. 2005). ZAP-70 has also 
been found in normal B-lymphocytes but only those showing a more 
activated phenotype and it has also been shown to be expressed in B-cell 
malignancies such as CLL and non-Hodgkin’s lymphoma (Nolz et al 
2005).
ZAP-70 was first identified in CLL samples following microarray 
experiments. Importantly, it was shown to be differentially expressed in 
patients with unmutated Vh genes. These patients showed five times
15
Chapter 1
greater transcription of the gene than the mutated cases (Orchard et al. 
2004;Wiestner et al 2003). More recently, ZAP-70 has been shown to 
enhance the signalling capacity of CLL cells following stimulation of the 
BCR (Chen et al. 2006;Schroers et al 2005). Previous research groups have 
suggested that the absence of ZAP-70 rather than its presence might be 
considered abnormal in CLL B-lymphocytes (Scielzo et al. 2006). In 
addition, Rassenti et al ( 2004) stated that the presence of ZAP-70 (>20%) 
was a stronger predictor of the patient needing treatment than Vh gene 
mutation status.
a
ZAP70 negative 
ZAP70 positive
0.8 -
0 .6 -
0.4 -
s
0.2 -s
log-rank test 
p <  0.0010.0 -
0 100 200 300 400 500
m onths
Figure 1.3 Kaplan-Meier curves showing time to first treatment for patients 
who expressed ZAP-70 and those who were ZAP-70 negative (Schroers, 
Griesinger, Trumper, Haase, Kulle, Klein-Hitpass, Sellmann, Duhrsen, & 
Durig 2005).
The patients who had > 20% ZAP-70 expression had a shorter time to first 
treatment than those patients who had < 20% ZAP-70 expression.
It has been shown that ZAP-70 is a marker for poor prognosis as it is 
associated with rapid progression, short time to first treatment and poor 
survival (Durig et al. 2002;Wiestner 2005). It has been suggested that ZAP-
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70 expression is a superior marker of prognosis than CD38 expression 
because it is thought the ZAP-70 expression levels do not change over time 
and has been shown to have strong predictive power of those CLL patients 
who will need treatment (Rassenti et al. 2004). However, there is still much 
controversy about the reliability of the methods used for measuring ZAP- 
70.
1.7 Treatment
Treatment is not given to all CLL patients. The disease is observed and 
those patients who show an aggressive and progressive disease receive 
treatment. The factors used to justify therapy are summarised as follows:
• Disease related symptoms
• Anaemia or thrombocytopenia due to bone marrow infiltration
• Autoimmune haemolytic anaemia or thrombocytopenia
• Bulky lymphadenopathy and/or splenomegaly causing compressive 
problems
• High blood lymphocyte count (>150 X 109/L)
• Rapidly increasing blood lymphocytosis (i.e. LDT <12 months)
• Increased susceptibility to bacterial infections
• Massive lymphocytic infiltration of bone marrow (i.e. diffuse 
histopathological pattern or >80% lymphocytes in bone marrow 
aspirate)
• Complex cytogenetic abnormalities
• Advanced clinical stage (Montserrat & Rozman 1994)
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If these factors are not displayed then the patient is usually monitored for 
disease progression but does not receive immediate treatment (Rai 1996). It 
has been shown that patients with early stage CLL do not display a survival 
advantage if they receive chemotherapy before they show disease 
progression (Brugiatelli et al. 2006).
Chlorambucil was the first line treatment for patients with CLL but it was 
suggested that long term toxicity, for example secondary cancers, was 
slightly increased in patients that had been treated with chlorambucil. 
Purine analogues were then produced, such as fludarabine, and these were 
found to produce higher complete remission rates and quality of life for the 
patient. Treatment with fludarabine increased the risk of opportunistic 
infection (Brugiatelli et al 2006).
Monoclonal antibodies were then developed such as Alemtuzimab (anti- 
CD52) and Rituximab (anti-CD20) (Wierda 2006). Rituximab is used in 
combination therapies such as FCR (fludarabine, cyclophosphamide and 
rituximab). This combination therapy showed a higher complete remission 
and overall response.
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1.8 Fludarabine
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Figure 1.4: Structure of fludarabine
(http://www.neuro.wustl.edu/neuromuscular/pics/diagrams/drugs/fludarabin
e2.jpg)
Fludarabine has been shown to be an effective single agent in the treatment o f  
CLL when considering complete remissions as an end-point (Brugiatelli et al 
2006).
Fludarabine (9-p-D-arabinofuranosyl-2-fluro-adenine 5’ monophosphate) 
(Keating et al. 1994) is a purine nucleoside analogue used in the treatment 
of CLL. Within 5 minutes of intravenous infusion fludarabine 
monophosphate is dephosphorylated into 9-(3-arabinofuranosyl-2- 
fluoroadenine (F-Ara-A). Once transported into the cell, F-Ara-A is 
converted into its active state F-Ara-A triphosphate (F-Ara-ATP) (Ross, 
McTavish, & Faulds 1993). Purine analogues promote apoptosis by 
inhibiting DNA polymerase and ribonucleotide reductase. Fludarabine can 
also inhibit transcription by its ability to be incorporated into RNA as well 
as DNA. The major side effects of fludarabine are myelosuppression, 
haematological and immunological toxicities, autoimmune haemolytic 
anaemia and at very high doses, there is significant neurotoxicity. When 
used in combination chemotherapy such as FC (Fludarabine and 
cyclophosphamide), the side effects are alopecia, vomiting, diarrhoea and 
cardiac toxicity (Dighiero & Binet 2000).
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Fludarabine was originally administered in an intravenous form. However, 
an oral form of fludarabine has been recently introduced (a lOmg tablet) 
that has been found to be a more convenient way to administer the therapy. 
Previous studies have shown that fludarabine induced complete or partial 
remission in most CLL patients (Ross, McTavish, & Faulds 1993). 
Montserrat and Rozman found that 83% of previously untreated patients 
responded to treatment with fludarabine and 75% achieved complete 
remission, whereas in previously treated patients there was a response rate 
of 57% with only 29% achieving complete remission (Montserrat & 
Rozman 1994).
Recently fludarabine has been used in combination therapy such as FC 
(fludarabine and cyclophosphamide) and most recently FCR (fludarabine, 
cyclophosphamide and rituximab). FCR therapy has been shown to have an 
improved complete response rate with the German CLL study group 
finding that this combination therapy produced a response rate of 95% and 
a complete response rate of 71% (Hallek 2005). Similarly Keating et al 
also found that treatment with FCR had a complete response rate of 70% 
(Brugiatelli et al 2006;Keating et al. 2005).
1.9 Apoptosis
There are two main pathways by which apoptosis is induced; the intrinsic 
pathway and the extrinsic pathway. These two pathways are in no way 
mutually exclusive as they interact at various points throughout both
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Figure 1.5 Apoptosis Pathway (Mak & Yeh 2002)
The extrinsic pathway and intrinsic pathway are the pathways that lead to 
apoptosis. They are not independent pathways as they interact via the apoptotic 
protein Bid.
1.9.1 Extrinsic Pathway
The extrinsic pathway is activated by cell-surface death receptors, such as 
the Fas receptor (CD95). CD95 contains a death domain in the receptor tail 
which allow s protein-protein interactions. The death receptor recruits 
intracellular adaptor proteins that also contain a death domain i.e. Fas 
contains a death domain which can bind to both Fas-associated death 
domain (FADD) protein and receptor-interacting protein (RIP) (Mak & 
Yeh 2002). FADD then interacts with caspase-8, and through aggregation 
and close proximity caspase-8 is cleaved thereby activating it. Once 
activated, caspase-8 can either activate caspase-3 and hence apoptosis, or it
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can activate Bid and initiate apoptosis via the intrinsic pathway (Packham 
& Stevenson 2005).
1.9.2 Intrinsic Pathway
Activation of the intrinsic pathway occurs via many stimuli such as cellular 
stress, radiation and cytotoxic drugs. Various apoptotic stimuli, usually via 
Bcl-2 family proteins, control the release of cytochrome c from the 
mitochondria. The cytochrome c then combines with Apaf-1 and pro- 
caspase-9 to form the apoptosome. This then cleaves pro-caspase-9 to form 
the activated caspase-9, which then can activate caspase-3 and apoptosis 
(de Graaf, de Witte, & Jansen 2004;Packham & Stevenson 2005).
1.10 Bcl-2 family
Bcl-2 family proteins are key molecules in the control of apoptosis. There 
are at least 2 0  family members that have been identified and they can be 
divided into 3 groups dependent on their structure and function (Schimmer 
et al. 2003). Group I are the anti-apoptotic proteins which include Bcl-2 
and Bc1-Xl and they have four Bcl-2 sequence homology (BH) domains, 
BH1, BH2, BH3 and BH4 (Packham & Stevenson 2005). Mcl-1 (myeloid 
cell leukaemia-1) is also a Group I protein but does not contain the BH4 
domain (Packham & Stevenson 2005). Bax, Bok and Bak are the pro- 
apoptotic members of Group II and have sequence homology at BH1, BH2 
and BH3 domains and hence are termed multidomain pro-apoptotic 
proteins (Packham & Stevenson 2005). Group III only share the BH3
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domain and include the pro-apoptotic proteins Bid, Bik, Noxa and Bim  
(Bellosillo et al. 2002;Cory, Huang, & Adams 2003).
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Figure 1.6: Structure of the Bcl-2 family members (Packham & Stevenson 
2005)
Group I (anti-apoptotic), Group II (pro-apoptotic) and Group III (BH3 only) 
members o f the Bcl-2 family. The Bcl-2 homology (BH) and transmembrane 
(TM) domains are indicated for each group. These BH domains are short 
sequence motifs less than 20 amino acids in length. The TM domain is used in the 
targeting o f the proteins to the mitochondrial membrane.
Bax, Bid and Bad are usually found in the cytoplasm whereas Bcl-2, Bcl- 
X l and Bak are usually associated with the mitochondrial membrane 
(Bellosillo et al 2002). Bax is translocated to the mitochondrial membrane 
on the induction o f  cell death (Dewson et al. 2003). When this 
translocation occurs Bax undergoes a conformational change that exposes 
the NH 2-terminus and the COOH-terminus that target the mitochondria. 
Bak is also an important protein which can also release cytochrome c from 
the mitochondria, and conformational changes or up-regulation are thought 
to be necessary for the induction o f  apoptosis (Bellosillo et al 2002).
Within CLL cells there are high levels o f  Bcl-2 (Bairey et al. 2001;Hanada 
et al. 1993;Packham & Stevenson 2005;Pepper et al. 1999) and increased 
Bcl-2/Bax ratios have been associated with clinical outcome and patients
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with low Bcl-2/Bax ratios respond better to chemotherapy than patients 
with high Bcl-2/Bax ratios (Banneiji et al. 2003;Moshynska et al. 
2004;Pepper, Hoy, & Bentley 1997). Patients who failed to achieve 
complete remission after drug therapy were found to have higher Mcl-1 
expression and high Mcl-1 /Bax ratios (Bellosillo et al 2002). Investigations 
showed that after treatment with fludarabine Bcl-2 and Mcl-1 expression 
decreased and expression of Bax and p53 increased (Cuni et al. 2004).
1.11 Survival pathways
Many survival pathways are constitutively activated in CLL cells. Cuni et 
al (Jiang et al. 2000) showed that NF-kB is constitutively active in CLL 
lymphocytes and this may lead to activation of either the MAP kinase 
pathway or the phosphatidylinositol-3 kinase (PI3K) pathway. It is thought 
that dysregulation of these survival pathways leads to failed apoptosis and 
therefore contributes to the accumulation of CLL lymphocytes.
1.11.1 PI3 Kinase pathway
Insulin and many other growth factors can activate the PI3 kinase pathway. 
PI3 kinase catalyzes the phosphorylation of inositol phospholipids at the 3 
position to generate phosphatidylinositol 3,4,5-triphosphate and 
phosphatidylinositol 3,4-bisphosphate (Vara et al. 2004). The PI3Ks are 
heterodimers consisting of a catalytic subunit, pi 1 0 , and a regulatory 
subunit, p85 (Jiang, Zheng, Aoki, & Vogt 2000). This pathway is involved
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in cell adhesion, vesicular trafficking, protein synthesis and cell survival 
(Waite & Eng 2002).
1.11.2 PTEN
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a 
54kDa protein and a member of the protein tyrosine phosphatase family. 
PTEN plays a major role in the control of the PI3K pathway by de- 
phosphorylating PIP3 at the 3' position, which is essential for translocation 
of Akt to the plasma membrane for activation (Leslie & Downes 2004). 
With PIP3 deactivated, Akt activation is reduced and therefore downstream 
signalling is also reduced. PTEN has a relatively high constitutive activity 
as it has been shown to lack obvious regulatory domains (Leupin et al. 
2002). In CLL there has been shown complete loss of heterozygosity at 
10q23.3 and allelic imbalances in PTEN expression which lead to loss in 
PTEN protein expression (Ballif et al. 2001).
1.11.3 PDK1
PDK1 (3-phosphoinositide-dependent kinase 1) is a serine/threonine kinase 
which is involved in the phosphorylation and activation of the AGC kinase 
super family (named after the family members protein kinase A, protein 
kinase G and protein kinase C) (Gao & Harris 2006) by phosphorylation of 
threonine (Thr) in the conserved activation loop region (Ballif et al 
2001;Feldman et al. 2005). These include Akt/PKB, protein kinase C 
(PKC), PKC-related kinases (PRK1 and PRK2), p70 ribosomal S6 -kinase 
(S6 K) and serum and glucocorticoid-related kinase (SGK) (Balendran et al.
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1999). It has also been suggested that when PDK1 interacts with PIF 
(PDK1 interacting fragment) it can also phosphorylate Akt at Serine 473 
(Carver, Aman, & Ravichandran 2000).
The phosphorylation activity of PDK1 is often dependent on the presence 
of PIP3. PIP3 has a pleckstrin homology (PH) domain, which PDK1 also 
possesses(Piccolo et al. 2004). PDK1 binds to PIP3 and is translocated to 
the plasma membrane where it can phosphorylate Akt on threonine 308 
(Thr308) (Balendran et al 1999). PDK1 can phosphorylate certain 
molecules independently of PIP3. One such molecule is S6 K which is 
downstream of mTOR and is involved in protein synthesis (Balendran et al 
1999). PDK1 can phosphorylate S6 K at Thr 252 and it has also been 
suggested that it can phosphorylate Thr 412 as well (Hay 2005).
1.11.4 Akt
Akt is an important member of the PI3K pathway and its activation is 
associated with resistence to apoptosis, increased cell growth and cell 
proliferation (Kawakami et al. 2004). It has a catalytic domain at its C- 
terminal and a pleckstrin homology domain at its N-terminal (Cuni et al 
2004). Akt is activated by phosphorylation at two sites, threonine 308 
(Thr308) and serine 473 (Ser473) (Kawakami et al 2004). Is it firstly 
phosphorylated on Thr308 in the activation loop of the kinase domain by 
PDK1 and then phosphorylated on Ser473 in the C-terminal hydrophobic 
motif by an unknown molecule that has been termed PDK2 (Bayascas & 
Alessi 2005;Feng et al. 2004). Phosphorylation at both sites is needed for
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activation of the Akt molecule. Suggested molecules for the elusive PDK2 
have been mTOR-rictor, PDK1 and Akt itself (Fait et al 2005;Hay 2005). 
Once activated, Akt can phosphorylate over 9000 proteins (Barragan et al.
2002). One of these molecules is the apoptotic protein Bad (Datta et al. 
1997;Downward 2004). Akt phosphorylates Bad at Ser 136 preventing it 
from binding to the anti-apoptotic protein Bcl-2 and inactivating it, 
therefore the cell is protected from apoptosis (Franke et al. 2003).
Yano et al ( 1998) described a PI3K independent activation of Akt and its 
survival responses. They explain that Ca /calmodulin-dependent kinase 
kinase (CaM-KK) can phosphorylate Akt on Thr 308 residue independently 
of the PI3K pathway (Cuni et al 2004). Akt was found to be constitutively 
active within CLL lymphocytes providing an explanation to why CLL cells 
have an abnormally long life-span (Petroulakis et al. 2006).
1.11.5 mTOR
Mammalian target of rapamycin (mTOR) (also known as RAFT 
(rapamycin and FKBP12 target) or FRAP (FKBP12-rapamycin associated 
protein)) (Hay & Sonenberg 2004;Petroulakis et al 2006) is a very large 
protein which belongs to the family of Phosphoinositide kinase related 
kinases (PIKKs). It is involved in the control of translation by 
phosphorylating and activating S6 K and 4E, an eukaryotic initiation factor 
(Guertin & Sabatini 2005). mTOR phosphorylates and activates S6 K which 
in turn can activate S6  ribosomal protein. Phosphorylation of 4E-BP by 
mTOR allows 4E to become free to bind to the cap structure of mRNA as a
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part of the translation initiation complex (Hay 2005). There are at least 2 
distinct complexes in which mTOR can exist in: mTOR-Raptor 
(regulatory-associated protein of mTOR) which is rapamycin sensitive, and 
mTOR-rictor (rapamycin-insensitive companion of mTOR) which is 
rapamycin insensitive (Hay 2005). It is mTOR-rictor that has been put 
forward as the elusive “PDK2” which phosphorylates Akt on Ser-473 
residue and it is the mTOR-raptor that is involved in the phosphorylation of 
S6 K and 4E-BP, and has also been indicated in a negative feedback loop 
with Akt (Petroulakis et al 2006).
1.11.6 S6K and S6
S6 K is involved in the control of different steps of protein synthesis, cell 
growth and storage of amino acids. It has also been associated with cell 
cycle regulation. S6 K directly phosphorylates insulin receptor substrate 1 
(IRS-1) which inhibits PI3 kinase and Akt activation. Through this 
negative feedback loop, S6 K can regulate mTOR (Petroulakis et al 2006). 
S6  activation has been linked to enhanced translation of TOP mRNAs 
(mRNA that contains a terminal 5’ oliopyrimidine tract) which encode 
ribosomal proteins, elongation factors and many other factors that are 
involved in translation in response to growth factors.
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1.12 Project aims and objectives
CD38 has been shown to be an important prognostic factor within CLL, but 
to date there is no biological rationale for why CD38 is associated with 
poor prognosis. Therefore, the aims of this present study were as follows:
• Determine whether CD38 is prognostic in our cohort of CLL 
patients
• Establish whether CD38 expression changes over time in CLL 
patients
• Isolate purified CD38+ and CD38' cells from the same CLL patient 
and establish whether they have a distinct transcriptional signature?
• Investigate whether CD38+ cells regulate the PI3K pathway 
differently to CD38‘ cells?
• Determine whether CD38+ cells regulate their response to apoptotic 
signals differently when compared to CD38' cells?
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Primary antibodies
Antibody Clone Volume
(111)
Company Catalogue
No.
Akt 2 . 0 Cell Signaling Technologies via New 
England Biolabs, Ipswich, MA, USA
9272
Akt-1 B-l 5.0 Santa Cruz Biotechnology, CA, USA sc-5298
Bax-FITC B-9 7.0 Santa Cruz Biotechnology sc-7480
Bcl-2-FITC 124 7.5 Dako Cytomation, Ely, UK F7053
p-actin 2 . 0 Cell Signaling Technologies 4967
CD19-APC SJ25-C1 4.0 Caltag Laboratories, Botolph Claydon, 
UK
MHCD19
05
CD38-RPE HIT2 4.0 Caltag Laboratories MHCD38
04
IL-lp H-153 4.0 Santa Cruz Biotechnology sc-7884
Ki67 MIB-1 8 . 0 Dako Cytomation F7268
Mcl-1 S-19 7.5 Santa Cruz Biotechnology sc-819
PDK1 2 . 0 Cell Signaling Technologies 3062
Phospho- 
Akt 1/2/3 
(Ser 473)
5.0 Santa Cruz Biotechnology sc-7985-R
Phospho- 
Akt 1/2/3 
(Thr 308)
5.0 Santa Cruz Biotechnology sc-16646- 
R
Phospho- 
Akt (Ser 
473)
2 . 0 Cell Signaling Technologies 405 IS
Phospho- 2 . 0 Cell Signaling Technologies 9275L
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Akt (Thr 
308)
Phospho-
S6
ribosomal
protein
(Ser235/
236)
2 . 0 Cell Signaling Technologies 2211L
p-Tyr PY20 8 . 0 Santa Cruz Biotechnology sc-508
S6
Ribosomal
Protein
2 . 0 Cell Signaling Technologies 2 2 1 2
VEGF C-l 4.0 Santa Cruz Biotechnology sc-7269
VEGFR2
(Flk-1)
A-3 4.0 Santa Cruz Biotechnology sc-6251
ZAP-70- 
Alexa 
Fluor 488 
conjugate
4.0 Caltag laboratories MHZAP7
0 2 0
Table 2.1: Primary Antibodies. Details of supplier, catalogue number, clone and 
experimentally-determined titration of each antibody.
2.1.2 Secondary antibodies___________________________ ___________
Antibody Volume
(Ml)
Company Catalogue
No.
ECL anti-mouse IgGi, peroxidase linked species- 
specific whole antibody (from sheep)
1 . 0 Amersham
Biosciences
NA931
ECL anti-rabbit IgGi, peroxidase linked species- 
specific whole antibody (from donkey)
1 . 0 Amersham
Biosciences
NA934
Polyclonal rabbit anti-mouse 
immunoglobulins/FITC
7.5 Dako
Cytomation
F0313
Polyclonal swine anti-rabbit 
immunoglobulins/FIT C
7.5 Dako
Cytomation
F0054
Table 2.2: Secondary antibodies. Details of supplier, catalogue number and 
experimentally-determined titration of each antibody.
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2.1.3 Amersham Biosciences, Buckinghamshire, UK
• ECL advance™ enhanced chemiluminescence western blotting 
detection kit. Catalogue number: RPN2135
• Hyperfilm™ ECL high performance chemiluminescence film 18 x 
24cm 75
• sheets. Catalogue number: RPN3103K
2.1.4 BioRad, Hemel, Hempstead, UK
• Quick Start™ Bradford dye reagent (IX). Catalogue number: 500- 
0205
• Quick Start™ Bovine serum albumin (BSA) 2mg/ml. Catalogue 
number: 500-0206
2.1.5 Calbiochem via Merck Biosciences Ltd., Nottingham, UK
• SU1498 VEGFR2 inhibitor 5mg. Catalogue number: 572888
2.1.6 Cell Signaling Technologies via New England Biolabs, Ipswich,
MA, USA
• Jurkat extracts Calyculin A treated. Catalogue number: 9273
• LY294002 treated Jurkat Extracts. Catalogue number: 9273
2.1.7 Dako Cytomation, Ely, UK
• Polyclonal rabbit anti-human IgM l.Omg/ml Catalogue number: 
A0426
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• Intrastain: Fixation and permeabilisation kit for flow cytometry. 
Catalogue number: K2311
2.1.8 Invitrogen, Paisley, UK
• Heat inactivated foetal calf serum (FCS). Catalogue number: 
10108-157
• Invitrolon™ PVDF filter paper sandwich 0.45jnm pore size. 
Catalogue number: LC2005
• MagicMark™ Western protein standards. Catalogue number: 
LC5600
• MultiMark™ Multi-coloured standards (IX), 500pl. Catalogue 
number: LC5725
• NuPAGE™ 4-12% Bis-Tris gels 1.0mm x 10 wells. Catalogue 
number: NP0321BOX
• NuPAGE™ Antioxidant 15ml. Catalogue number: NP0005
• NuPAGE™ LDS sample buffer (4X) 10ml. Catalogue number: 
NP0007
• NuPAGE™ MOPS SDS running buffer (20X) 500ml Catalogue 
number: NP0001
• NuPAGE™ sample reducing agent (10X) 10ml. Catalogue number: 
NP0009
• NuPAGE™ transfer buffer (20X) 1L. Catalogue number: NP0006- 
1
2.1.9 Qiagen, Crawley, West Sussex, UK
• QIAamp DNA blood midi kit. Catalogue number: 51183
33
Chapter 2
2.1.10 Sigma Aldrich, Poole, Dorset, UK
• Ammonium chloride. Catalogue number: A-4514
• Histopaque-1077. Catalogue number: 10771-500ml
• Mammalian Cell Lysis Kit. Catalogue number: MCL-1
• Monoclonal anti-vascular endothelial growth factor, antibody 
produced in mouse. Catalogue number: V4758-5MG
• Paraformaldehyde. Catalogue number: P-6148
• Phosphate buffered saline tablets, 100 tablets. Catalogue number: 
P-4417
• Polyoxyethylenesorbitan Monolaurate (Tween 20). Catalogue 
number: P-1379
• RPMI-1640 Medium Sterile filtered with L-glutamine and 
NaHCC>3. Catalogue number: R8758
• Sodium chloride. Catalogue number: S-5886
• Trizma hydrochloride, SigmaUltra, >99% titration. Catalogue 
number: T6666-250G
• Vascular endothelial growth factor 121, human recombinant. 
Expressed in E-coli. Catalogue number: V3388-5UG
2.1.11 Thermo Electron Corporation, Cambridge, United Kingdom
• Finntip5ml sterilized 5 x 54 pcs/rack. Catalogue number: 9402073
• Finntip 10 10 x 96 pcs/rack. Catalogue number: 9400300
• Finntip 250 universal sterilized 10 x 96 pcs/rack. Catalogue 
number:9400263
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• Finntip 1000 sterilized 10 x 96 pcs/rack. Catalogue number: 
9401113
2.1.12 Fludarabine was kindly donated by Dr Christopher Fegan, 
Department of Haematology, Llandough Hospital, Penlan Road, Penarth, 
Cardiff, UK.
2.2 Equipment
Agilent bioanalyzer (Agilent Technologies UK Limited)
Beckman Coulter Z2 Cellular Counter (Beckman Coulter)
DNA Thermo Cycler (ABI)
FACScan (Becton Dickinson)
FACSCalibur (Becton Dickinson)
MoFlo high speed cell sorter (Dako Cytomation)
2.3 Methods
In a number of the kits that were used in these experiments the exact 
composition of the different solutions were not provided by the 
manufacturers.
2.3.1 Patients and samples
Ethical approval for this project was obtained from Bro Taf Local Research 
Ethics Committee panel B (# 02/4806). Peripheral blood was obtained from 
unselected patients attending outpatient clinics at Llandough Hospital and 
Birmingham Heatlands Hospital with their informed consent. None of the
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patients who had previously undergone chemotherapy had received 
treatment within 3 months of their study sample being taken.
2.3.2 Isolation of lymphocytes
Lymphocytes were separated by density centrifugation on Histopaque-1077 
(300 x g for 30 minutes). This is a polysucrose (5.7g/dl) and sodium 
diatrizoate (9.0g/dl) solution which is adjusted to a density gradient 
1.077g/cm3. This allows the erythrocytes and granulocytes to sediment 
whilst trapping mononuclear cells (including lymphocytes) at the plasma- 
histopaque interface. The lymphocytes were aspirated into a sterile 
centrifuge tube, to which phosphate buffered saline (PBS) was added, and 
the cells were spun at 300 x g for 10 minutes. Subsequently, 0.87% 
ammonium chloride was added to lyse any contaminating erythrocytes and 
spun for 10 minutes at 300 x g. The cells were washed again in PBS and 
centrifuged again at 300 x g for 10 minutes. This washing step was then 
repeated and the numbers of lymphocytes were counted using a Beckman 
Coulter Z2 Cellular Counter. The cells were subsequently aliquoted (1 x 
106 cells) into 5ml Falcon tubes.
2.3.3 Determination of Vh gene mutation status
The BIOMED-2 procedure was carried out as described previously. 
(Matthews et al. 2004) This procedure was carried out by the Molecular 
Diagnostics Department of the Department of Haematology. The key 
elements of this procedure are outlined in the subsequent sections.
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2.3.3.1 DNA extraction
DNA was extracted using QIAamp DNA blood midi kit. In a 15ml 
centrifuge tube, 2ml of white blood cells (2 X 106 cells) was added to 
200jil of QIAGEN protease and was mixed briefly. To this 2.4ml of Buffer 
AL was added and the solution was mixed thoroughly by vortexing. The 
solution was incubated at 70°C for 10 minutes. Ethanol (2ml) was added to 
the sample and mixed by vortexing. Half the solution was added to the 
QIAamp midi column and this was centrifuged at 1850 x g for 3 minutes. 
The flow-through was discarded, and the rest of the solution was added to 
the column which was spun at 1850 x g for 3 minutes. The filtrate was 
discarded. 2ml of Buffer AW 1 was added to the QIAamp midi column and 
this was centrifuged at 4500 x g for 1 minute. 2ml of Buffer AW2 was then 
added to the QIAamp midi column and this was centrifuged at 4500 x g for 
15 minutes. The flow-through and collection tube was discarded and the 
QIAamp midi column was placed in a fresh 15ml centrifuge tube. 300pl of 
Buffer AE was pipetted directly onto the membrane of the QIAamp midi 
column, and with the cap closed, it was incubated at room temperature for 
5 minutes and then centrifuged for 5 minutes at 4500 x g. To obtain 
maximum DNA concentration, 300pl of eluate containing the DNA was 
reloaded onto the QIAamp midi column and was incubated at room 
temperature for 5 minutes. It was then centrifuged at 4500 x g for 5 
minutes. The DNA was kept for further down stream assays such as 
polymerase chain reaction.
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2.3.3.2 Polymerase Chain Reaction (PCR)
The DNA previously extracted was then used in a multiplexed PCR 
reaction with the BIOMED-2 primers.
VhI-FRI 5' GGCCTCAGTGAAGGTCTCCTGCAAG 3’
Vh2-FRI 5' GTCTGGTCCTACGCTGGTGAAACCC 3'
Vh3-FRI 5' CTGGGGGGTCCCTGAGACTCTCCTG 3'
Vh4-FRI 5' CTTCGGAGACCCTGTCCCTCACCTG 3'
Vh5-FRI 5' CGGGGAGTCTCTGAAGATCTCCTGT 3'
Vh6 -FRI 5' TCGCAGACCCTCTCACTCACCTGTG 3’
Jh
consensus
5' CCAGTGGCAGAGGAGTCCATTC 3'
Table 2.3: Sequences of BIOMED-2 primers
A 50jil solution was made up of 0.5pg of DNA sample, 10 pmol of each 
primer, 2 nM of dNTPs (deoxy nucleotide triphosphates), 1 U AmpliTaq 
Gold and 10X PCR buffer II. The DNA Thermo Cycler (ABI) was used as 
follows: denaturation at 94°C for 15 minutes; 35 cycles of 94°C for 30 
seconds, 58°C for 30 seconds and 72°C for 30 seconds; and a final cycle of 
10 minutes at 72°C.
2.3.3.3 Analysis
The PCR products were analysed on the Agilent bioanalyzer. The products 
were then sequenced directly using 3* Jh consensus primer in an automated 
ABI Prism 3100 genetic analyser using Big-Dye terminators. Comparison 
of the derived sample sequence was made with germline sequences stored
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on the Ig Blast database (http://www.ncbi.nlm.nih.gov/igblast/) and the 
percentage sequence homology to the closest germline sequence was 
determined. Both the percentage sequence homology and the Vh gene 
segment usage for each patient sample were noted.
2.3.4 Cell culture
Cells were cultured in RPMI-1640 Medium supplemented with penicillin 
(10,000 units/ml), streptomycin (lOmg/ml) and 10% foetal calf serum 
(FCS). These cells were then incubated at 37°C, in 5% CO2 for a fixed 
period of time.
2.3.4.1 Drug sensitivity
The cells were set up in culture as described in 2.3.4 and the purine 
nucleoside analogue drug, fludarabine, was added at final concentrations of 
2pM -  8pM. In addition, control cultures were set up without the addition 
of fludarabine. The samples were incubated at 37°C for 48 hours, after 
which the cells were spun at 300 x g for 5 minutes and used in a number of 
downstream assays.
2.3.4.2 Inhibitors
Lymphocytes were set up in culture as described in 2.3.4 and inhibitors 
were added as in Table 2.1. Control cultures contained no inhibitor.
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Inhibitor Concentration Added
SU1498 lOpM
Monoclonal anti-VEGF lpg/ml
Table 2.4: Type of inhibitors added to the cultures
The name and type of inhibitor is given in this table along with the concentrations 
used.
The cells were incubated for 24 hours at 37°C. They were then harvested 
by centrifugation and analysed by flow cytometry.
2.3.4.3 Recombinant VEGF
The cells were set up as described in 2.3.4 and cultured for 24h with or 
without lOOng/ml recombinant VEGF. The cells were then used in 
subsequent phenotyping experiments (2.3.5) and apoptosis assays (2.3.8)
2.3.5 Flow cytometry
Flow cytometry enables the discrimination of distinct cellular populations 
based on differential light scatter and fluorescence characteristics. The 
process of flow cytometry involves focusing cells into a unicellular stream 
of fluid and passing the stream through a laser beam. With early flow 
cytometry systems there were great problems with large cells or clumps of 
cells blocking the capillary fluidics system. In modem day flow cytometry 
systems this is overcome by the principles of laminar flow (The Bernoulli 
effect) and hydrodynamic focusing. The Bernoulli effect results in the cells 
remaining in the centre of the fluid as this is where there is least pressure 
and the velocity is greater. Velocity is slower at the edges as there is 
viscous drag along the walls of the tubing. Hydrodynamic focusing
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involves introducing cells in suspension through a large tube with a larger 
tube around it containing sheath fluid. By reducing the size of the tube, and 
maintaining laminar flow, a unicellular stream of cells can be produced 
(Figure 2.1 A).
The Bernoulli Effect Hydrodynamic focusing
S '
S heath  Fluid ooo °8 o Ooo o o o —*
Direction of flow 
Figure 2.1 A: Principles of flow cytometry
(http://www.cardiff.ac.uk/medicine/haemotology/cytonetuk/introductio
ntofcm/fluidics.htm)
By combining the principles of laminar flow and the Bernoulli Effect a 
stream of cells can be produced with reduced risk of blocking by large cells 
and clumps.
The cells are then passed through a laser beam. As the cell passes through 
the beam there is absorption, diffraction, refraction and reflection of light 
as well as fluorescence which is the emission of longer wavelengths 
following excitation and relaxation of electron states. The characteristics of 
the cell can be determined by the amount of light scatter and fluorescence 
identified by a range of detectors (Figure 2. IB). Differential forward light 
scatter informs on the size of the cell and the amount of side scatter 
indicates the granularity of the cell. A photomultiplier tube (PMT) detects 
the fluorescence emitted from the cell and converts it into electrical pulses. 
Different filters are used to discriminate between the different wavelength 
fluorescent signals e.g. FL1 -  fluorescein isothiocyanate (FITC), FL2 -  R-
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phycoerythrin (PE) and FL4 -  allophycocyanin (APC). Computer software 
is used to analyse the electrical pulses.
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Figure 2.IB: Basic optical layout of a FACS Calibur flow cytometer
Diagram of the layout of the lasers and the flourochromes that can be 
quantified by each detector. This diagram was produced by The Scripps 
Research Institute and was found at www.facs.scripps.edu/facslab.html.
The emission maxima for the fluorochromes that were routinely used in 
this study are; FITC 530nm, PE 570nm and APC 650nm (Figure 2.1C). 
The emission spectra for the 3 fluorochromes have very little overlap, so 
little compensation needs to be carried out. If there was a great amount of 
overlap then compensation need to be carried out in which the computer 
applies an algorithm to define the overlap between the 2 fluorescent 
signals.
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FITC'
600
W avelength  (nm
Figure 2.1C: Emission spectra for FITC, PE and APC (Diagram 
obtained from
http://www.urmc.rochester.edU/research/cellsort/ppt/basic.ppt#274,7,si 
ide7).
2.3.6 Labelling of lymphocytes
Samples from all the patients were analyzed by triple-colour 
immunofluorescent staining using a combination of the protein under 
investigation in conjunction with CD38 and the pan B-cell marker CD 19. 
Isotype-matched controls were also set up for each antibody. 1 x 106 cells 
were incubated with 4|Ltl of CD38 R-phycoerythrin (PE) conjugated 
antibody and 4  jul of CD 19 Allophycocyanin (APC) conjugated antibody. 
The cells were then fixed using a commercially available kit (caltag) and 
resuspended in permeabilisation solution together with titration-determined 
volumes of each antibody. Briefly, 50|xl of Solution A was added to the 
samples and they were incubated in the dark for 15 minutes. The cells were 
washed in PBS and spun at 300 x g. Solution B (50ml) was added to the 
cells along with titration-determined volumes of the desired antibody, 
incubated in the dark for 15 minutes and then washed in PBS and spun at 
300 x g. A fluorescein isothiocyanate (FITC) labelled secondary antibody
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was added to all the samples that were not pre-conjugated and the cells 
were then resuspended in 1% parafomaldehyde prior to flow cytometric 
analysis using a FACSCalibur flow cytometer employing CellQuest Pro 
software. Isotype-matched negative control antibodies were utilized to set 
the threshold for non-specific binding. From each sample at least 10,000 
cells were analyzed. Gating using forward scatter and side scatter and 
gating of the CD19+ cells ensured that protein expression was quantified in 
the viable B-lymphocyte population. The mean fluorescent intensity (MFI) 
was calculated for each protein using WinMDI software (J. Trotter, Scripps 
Research Institute, La Jolla, CA) (Figure 2.2)
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Figure 2.2: Analysis of FACSCalibur data.
These three dot plots show the gating strategy employed throughout the 
investigation. A) Gating of the total viable lymphocyte population (Rl- 
red). B) Gating of the CD19+ B-lymphocyte population only (R2-green). 
C) Gating of CD38+ (R4-blue) and CD38‘ (R3-purple) cells from the viable 
B-lymphocyte population.
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2.3.7 Labelling of lymphocytes with Ki-67
The lymphocytes were labelled as above except when the permeabilisation 
solution was added to the cells, lpl of Nonidet P40 was also added, along 
with the Ki-67-FITC antibody, and it was incubated for 15 minutes at 4°C. 
The cells were then washed and re-suspended in 1 % paraformaldehyde and 
analysed as above.
2.3.8 Annexin V Assay
1 x 106 cells were resuspended in 196pl of calcium-rich binding buffer 
(which had been diluted 1:4). Annexin V-FITC (4pl) was then added to the 
cells, and they were incubated in the dark for 10 minutes. Within 1 hour the 
cells were analysed on the FACSCalibur. Just before the analysis, 8pl of 
propidium iodide (concentration 10pg/ml) was added to the cells.
2.3.9 Fluorescence Activated Cell sorting (FACS)
Fluorescence activated cell sorting (FACS) using the MoFlo high speed 
cell sorter is the process of physically sorting cells into defined groups. 
The MoFlo uses the stream in air method where the nozzle is vibrated with 
a transducer which helps the stream to break up into droplets. The flow of 
sample and sheath fluid is adjusted so that the cells can be placed into 
droplets separated by droplets not containing any cells. The sheath fluid is 
usually PBS, and the stream is electrically charged just before the droplet 
separates from the stream which allows three populations to be selected 
after passing through the electronic field (positive, negative or neutral). 
Three droplets are sorted per cell allowing the cell to be in adjacent drops
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to that expected, and the sort is aborted electronically if this set of droplets 
is followed directly by another cell as this helps to avoid contamination 
with the unwanted cells. By increasing the number of droplets per cell the 
purity can be improved and by over-riding the abort mechanism, the 
recovery is increased (Figure 2.3).
1 0  0 0 The nozzle w as vibrated by the tran sd u cer to break  
the stream  into droplets
L aser
W hen the drop rea ch es  break off point it is 
charged; blue = positive, red = negative
The electrostatic field deflects the charged  
droplets to the right or to the  left
0 0 0  0 0 0  0 0 0  The cells a re  collected in appropriate collection
  right devices; tubes, multi-well p la tes etc.
W aste
Figure 2.3: Principles of MoFlo high speed cell sorting.
The MoFlo high speed cell sorter can sort up to 60,000 events/second.
Cells were labelled with CD5-FITC, CD38-PE and CD19-APC. These cells 
were physically sorted into CD5+/CD38+/CD19+ and CD5+/CD38'/CD19+ 
sub-populations by high speed cell sorting (up to 35,000 events/second) 
using a MoFlo High Speed Cell Sorter. This was carried out by Dr. Chris 
Pepper, Department of Haematology. The resultant cell populations were 
aliquoted into appropriate volumes for downstream assays such as cell 
cycle analysis (1 x 106 cells) and RNA extraction (1 x 107 cells) for micro­
array analysis.
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2.3.10 Cell cycle analysis
Aliquots (1 x 106 cells) of the cell sorted CD38+ and CD38' sub-groups 
were fixed in ice cold 70% ethanol and were stored at -20°C for at least 30 
minutes. They were then washed in PBS, treated with RNase A (1 mg/ml) 
and stained with propidium iodide (400pg/ml) for 30 minutes at 37°C. The 
cells were analysed using a FACScan flow cytometer using 488nm 
excitation. Cell cycle distribution was quantified using a complex 
mathematical algorithm using Cylchred version 1.0.2 software.
i i i i i i i i i i
100  200  300  400  5 0 0  6 0 0  700  80 0  90 0  10 0 0
Figure 2.4 Cell Cycle distribution
The first red peak at 200 represents the cells that are in Go/Gi. The green 
represents the cells that are in S phase. The second red peak at 400 
represents the cells that are in G2 .
2.3.11 Protein extraction
3 x 107 cells were lysed in 100(il of Mammalian Cell Lysis kit lysis buffer 
(Sigma Aldrich, Poole, Dorset, UK), and incubated on ice for 15 minutes. 
The cells were then sonicated ( 3 x 5  second bursts followed by 5 second 
intervals), and the cell debris was collected by density centrifugation (300 
x g for 5 minutes). The supernatant was transferred into a new sterile tube.
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For each sample a 1:20 dilution was carried out and 5jli1 of this was added 
to a 96 well plate in duplicate. Dilutions of bovine serum albumin (BSA) 
(0-1.0pg/ml) (BioRad, Hemel, Hempstead, UK) were also added in 
duplicate to the 96 well plate. The protein concentration was determined 
using the Bradford Assay (BioRad) and this was read at 595nm. Using the 
absorption values, a standard curve was produced for the dilutions of BSA. 
From the curve the quantity of protein for each sample was deduced.
2.3.12 Sodium dodecyl sulphate- Polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting
Sodium dodecyl sulphate- Polyacrylamide gel electrophoresis separates 
proteins on the basis of size, using an electric current. The XCell 
SureLock™ Mini-Cell was set up according to the manufacturer’s 
instructions. 20pg of protein sample was added to each lane of a pre-cast 
Novex 4% - 12% Bis-Tris (Bis (2 - hydrpxyethyl) iminotris
(hydroxymethyl) methane) gel, along with ljj.1 of MagicMark™ and 5pi of 
MultiMark™. Appropriate positive and negative controls were also used to 
ensure correct band identification. The MOPS (3-(N- 
morpholino)propanesulfonic acid) SDS running buffer was diluted to a 
1:20 solution and was added to the XCell SureLock™ Mini-Cell. The gel 
was run for 50 minutes at a constant voltage of 200V. While the gel was 
running, a poly vinylidene difluoride (PVDF) membrane was pre-soaked in 
methanol. It was then soaked, along with the blotting pads and filter paper, 
in transfer buffer (consisting of transfer buffer (50ml), NuPage™
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Antioxidant (1ml), methanol (100ml per gel) and deionised water to a final 
volume of 1L). Once the SDS-PAGE was complete, the gel was removed 
from its plastic casing, and the XCell SureLock™ Mini-Cell was rinsed of 
all running buffer. The gel/membrane sandwich was set up as follows 
(Figure 2.5):
Blotting Pad 
Blotting Pad
Filter Paper
PVDF
-Gel
Filter Paper 
Blotting Pad
-Blotting Pad
Figure 2.5: Layout of Western blotting apparatus
Two blotting pads next to the cathode core followed by filter paper, the gel, 
PVDF membrane, another filter paper, and 2 more blotting pads next to the 
anode lid.
Deionised water was added to the XCell SureLock™ Mini-Cell’s “outer 
core” to dissipate the heat. The blotting conditions were 30V for 1 hour. 
Once transfer was complete, the membrane was washed in deionised water 
and then placed in 5% non-fat milk blocking solution (made in TBS (Tris 
buffered saline) with 0.1% Tween-20) for an hour. The primary antibody 
was diluted in a 5% non-fat milk solution according to the manufacturer’s 
recommendations. This was added to the membrane, which was placed at 
4°C on a gel rocking platform overnight.
Membranes were then rinsed in TBS-Tween (0.1% Tween 20), and a 
secondary antibody (diluted in a 5% non-fat milk solution) was added to 
the membrane for an hour. This was rinsed off using TBS-Tween (4x 5 
minute washes). The ECL™ (Amersham) advance kit was used to detect
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the bands on the gel, which was developed onto Hyperfilm™ ECL high 
performance chemiluminescence film (Amersham).
2.3.13 Microarray
Microarray is the process in which the expression of thousands of genes 
can be measured simultaneously. Fragmented RNA is labelled with a 
fluorescent tag (fluorescent labelled biotin) and added to the microarray 
chip where, if there are any complimentary sequences, it can bind to the 
chip. The microarray is then scanned by a laser and the labelled RNA emits 
a fluorescent signal proportional to the amount of RNA that is bound. This 
is recorded by the camera and reproduced on the computer.
The microarray chips contain 11 to 20 probes for every transcript which 
match different parts of the 3' end of the mRNA sequence. The probes are 
made up of a pair of 25 residue oligonucleotides, one that is a perfect 
match to the transcript, and the other has had the middle residue changed 
and so is a “mismatch”. This helps to reduce the background signal and any 
non-specific binding. There are many different Microarray chips available 
and for a variety of different organisms. In this study, the human U133A 
array was used which contains 22,283 gene transcripts.
The process of Microarray (from RNA extraction to Scanning the 
chip) was carried out by Megan Musson in the Central Biotechnology 
Services. The key component steps involved in this procedure are 
described.
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2.3.13.1 RNA extraction
Trizol reagent was added the cell-sorted populations (1 x 107 cells), and 
this was placed in tubes containing Phase Lock Gel-Heavy and were 
incubated for 5 minutes at 37°C. 0.2ml of chloroform was added and the 
tubes were shaken. The samples were spun at 12,000 x g for 10 minutes at 
2-8°C, to separate the phases (the clear aqueous phase was on top and 
cloudy chloroform phase was on the bottom). The aqueous phase was 
transferred to a clean tube, and to which 0.6ml of isopropyl alcohol was 
added. The tubes were shaken, and spun as before. The pellet of RNA was 
re-suspended in 75% ethanol and centrifuged at 7,500 x g for 5 minutes at 
2-8°C. The supernatant was removed, and the pellet allowed to air dry. The 
pellet was re-suspended in RNase-free water, and incubated at 65°C for at 
least 30 minutes. The RNA was quantified using the Nanodrop 1000 
(Nanodrop Technologies), and the purity was checked by running an 
Agilent chip on the Agilent bioanalyzer (Agilent Technologies).
2.3.13.2 One-cycle cDNA synthesis
A 1:20 dilution of Poly-A (poly-adenine) control stock was made in Poly-A 
Control Dilution Buffer from the commercially available kit (Affymetrix). 
From this solution, 2pl was added to Poly-A control dilution buffer to 
make a 1:50 dilution. Again, 2jli1 was taken from this solution and added to 
Poly-A control dilution buffer to make a 1:10 dilution. 2pl of this final 
dilution was added to the sample of RNA.
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T7-01igo(dT) Primer was added to the RNA and the volume was made up 
to 12pl with RNase-free water. The reaction was incubated at 70°C for 10 
minutes and then cooled for at least 2 minutes. The First-Strand master mix 
was made up as follows: 4pl of 5X 1st strand master mix, 2pl 0.1M 
Dithiothreitol (DTT) and lpl lOmM dNTP. This was added to the 
RNA/T7-oligo(dT) primer mix and incubated at 42°C for 2 minutes. The 
appropriate amount of Superscript II was added to each RNA sample and 
incubated for 1 hour at 42°C. The sample was then cooled at 4°C for at 
least 2 minutes. The Second-Strand master mix was made up as follows: 
91 pi of RNase-free water, 30pl 5X 2nd strand reaction mix, 3pi lOmM 
dNTP, lpl E. coli DNA ligase, 4pl of E.coli DNA polymerase I and lpl 
RNase H. 130pl of this master mix was added to each RNA sample and it 
was incubated for 2 hours at 16°C. T4 DNA Polymerase (2pl) was added 
to the sample and was incubated at 16°C for 2 minutes. lOpl of 0.5M 
ethylene diamine tetra-acetic acid (EDTA) was added to the sample. cDNA 
(compliment DNA) Binding Buffer (600pl) was added to the sample 
making the mixture yellow. The sample was applied to the cDNA Cleanup 
Spin Column and spun at > 8,000 x g for 1 minute. The spin column was 
transferred into a new collection tube and cDNA Wash Buffer was added 
to the column. This was then spun at > 8,000 x g for 1 minute and the flow 
through was discarded. The caps of the spin columns were opened, 
centrifuged for 5 minutes at maximum speed and the collection tube and 
flow-through were discarded. The column membranes were dried by 
centrifugation and the spin columns were placed in clean collection tubes. 
cDNA elution buffer was added directly onto the column membrane and
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incubated for 1 minute at room temperature. This was then spun at 
maximum speed for 1 minute to elute.
2.3.13.3 Synthesis of biotin-labelled cRNA
The following solution was made up; 4jli1 10X IVT labelling buffer, 12pl
IVT (in vitro transcription) labelling NTP (nucleotide triphosphate) mix,
4(il IVT labelling enzyme mix, required amount of template cDNA and the
volume made up to 40pl with RNase-free water. The mixture was
incubated at 37°C overnight. The following day 60jll1 of RNase-free water,
350jlU cRNA  binding buffer and 250jnl ethanol was added to the sample,
which was applied to the IVT cRNA Cleanup Spin Column. This was spun
at >8,000 x g for 15 seconds, and the flow through and collection tube was
discarded. The spin column was placed in a new collection tube. 0.5ml IVT
cRNA wash buffer was added to the column and was spun as before with
the flow through being discarded. 80% ethanol (0.5ml) was added to the
sample and was spun as before. The spin column’s cap was opened and it
was spun at maximum speed for 5 minutes. The flow through and
collection tube was discarded. After a new collection tube was added, 16pl
of RNase-free water was added directly onto the membrane and the column
was spun at maximum speed for 5 minutes. This step was then repeated. To
quantify the cRNA the absorbance was read at 260nm and 280nm. The
yield was determined using the following equation;
Adjusted cRNA yield = RNAm -  (total RNAi)(y)
Where: RNAm = amount of cRNA measured after IVT (pg) 
Total RNAi = starting amount of total RNA (pg) 
y = fraction of cDNA reaction used in IVT
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2.3.13.4 Fragmenting the cRNA for target preparation
The fragmentation buffer was made up as follows; 20pg cRNA, 6jll1 5X 
fragmentation buffer, and the volume was made up to 40|il with RNase- 
free water. This solution was incubated for 35 minutes at 94°C, and then 
placed on ice. An aliquot was run on the Agilent Bioanalyzer to check the 
process had occurred.
2.3.13.5 Eukaryotic target hybridization
The probe array (Affymetrix U133A gene chip) was equilibrated to room 
temperature immediately before it was used. Hybridization cocktail was 
made up of fragmented RNA (1 OjLlg), control oligonucleotide B2 (3nM) 
(3.3jll1), 20X eukaryotic hybridization controls (bioB, bioC, bioD, ere) 
(10pl), Herring Sperm DNA (lOmg/ml) (2|ll), bovine serum albumin 
(BSA) (50mg/ml) (2|il) 2X hybridization buffer (1 OOjn.1), dimethyl 
sulfoxide (DMSO) (20pl) and water to make the final volume 200JJ.1. This 
was heated to 99°C for 5 minutes in a heat block.
While the hybridization cocktail was heating, the 130jll1 of IX 
Hybridization buffer was added to the array and it was incubated at 45°C 
for 10 minutes with rotation. The hybridization cocktail was transferred to 
a 45°C heat block for 5 minutes, and then was spun to remove any 
insoluble material. The buffer was removed from the array, and the 
hybridization cocktail (200|il) was added, and the array was placed in the 
Hybridization oven set to 45°C for 16 hours.
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2.3.13.6 Washing, staining and scanning
The fluidics station was primed with Non-stringent wash buffer and 
Stringent wash buffer before use. After hybridization, the cocktail was 
removed from the probe array, and the array was filled with non-stringent 
wash buffer. Three staining solutions were made up and place onto the 
fluidics station. Staining solutions 1 and 3 were 600pl Streptavidin 
Phycoerythrin (SAPE) solution made up of 600pl 2X stain buffer, 48pl of 
50mg/ml BSA, 12jll1 1 mg/ml SAPE, 540jil water. The 2nd stain solution is 
Antibody solution made up of 2X stain buffer (300|il), 50mg/ml BSA 
(24pl), lOmg/ml goat Immunoglobulin G (IgG) stock (6jll1), 0.5mg/ml 
biotinylated antibody (3.6|ll) and water (266.4|Lll). The fluidic protocol was 
as follows:
Post hybridization wash #1 10 cycles of 2 mixes/cycle with 
wash buffer A at 30°C
Post hybridization wash #2 6 cycles of 15 mixes/cycle with 
wash buffer B at 50°C
Stain Stain the probe array for 5 minutes 
in SAPE solution at 35°C
Post stain wash 10 cycles at 4 mixes/cycle with 
wash buffer A at 30°C
2nd Stain Stain the probe array for 5 minutes 
in antibody solution at 35°C
3rd Stain Stain the probe array for 5 minutes 
in SAPE solution at 35°C
Final wash 15 cycles at 4 mixes/cycle with 
wash buffer A at 35°C. The holding 
temperature is 25°C
Table 2.5: Fluid protocol for the fluidics station
The protocol states which wash buffer or stain is used, the amount of cycles and at 
what temperature this occurs.
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2.3.13.7 Analysis
Analysis of the microarray data was carried out on GeneSpring software 
(Agilent Technology). Firstly, any genes that were not present in at least 
one of the samples were removed from the gene list. Then any genes that 
had less than a 2 fold change were also removed. Statistical analysis was 
carried out (ANOVA test and Student’s t test) and a gene list produced 
after comparing the gene lists from the two tests and finding the genes 
present in both. The gene list was exported into Pathway Assist 
(Stratagene), where pathways were produced with any genes that were 
directly connected. Pathway assist connects to Pubmed 
(http://www.ncbi.nlm.nih.gov) and searches for any associations between 
the genes input. It then uses this information to build the pathway.
2.3.14 Statistical analysis
Statistical analyses were performed using both parametric and non- 
parametric methods depending on whether the data obeyed a Gaussian 
distribution. Statistical analyses were carried out using GraphPad Prism 3.0 
software.
If the data obeyed a Gaussian distribution the main parametric test that was 
carried out was an unpaired Student’s t test. If the data was derived from 
the same patient (such as when CD38+ and CD38‘ cells were analysed from 
a bimodal patient) then a paired Student’s t test was carried out. Correlation 
tests were also carried out on most of the data. If the data did not obey a 
Gaussian distribution then, depending on the type of data, different non- 
parametric tests were carried out such as a Mann-Whitney test, a Fisher’s
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Exact test or a Chi Squared test. Also, when analysing the CD38 
longitudinal data, an ANOVA was carried out. For each statistical test the 
value of significance used was P < 0.05. When carrying out the 
correlations, the r2 value was also investigated to determine how well the 
data clustered around the regression line.
58
Chapter 3
Chapter 3: CD38 expression as a prognostic marker in CLL
CD38 is now widely regarded as an important prognostic marker in CLL 
(Damle et al. 1999;Ghia et al. 2003;Hamblin et al. 2002;Schroers et al. 
2005;Thomton et al. 2004). However, areas of controversy remain that 
hamper its confident use namely: (1) the debate about whether CD38 is a 
surrogate marker of Vh gene mutation status (Damle et al 1999;Hamblin et 
al 2002); (2) the discordance in the literature about which cut-off value for 
CD38 expression best discriminates between CD38+ and CD38' cases in 
defining prognosis (Damle et al 1999;Ghia et al 2003;Ibrahim et al. 
2001;Krober et al. 2002); (3) the possibility that CD38 expression changes 
over the course of the disease and hence may be an unstable marker (Ghia 
et al 2003;Krober et al 2002); (4) the relationship between CD38 and the 
other well known prognostic and clinical markers used in CLL.
Aims: To investigate whether CD38 expression is a surrogate marker for 
Vh gene mutation status and whether CD38 expression is individually a 
prognostic marker.
Hypothesis: CD38 may correlate with Vh gene mutational status but could 
not be used as a surrogate marker. However CD38 could be used as an 
individual marker of prognosis.
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Number of patients
Sex (Male/Female) 102 66
Treated/U ntreated 119 49
Stage (Binet A/B/C) 111 25 32
VH Gene Satus 
(Mutated/Unmutated) 106 37
LDT (>12/<12) 138 28
Cytogenetics 
(13ql4/Trisomy 12/6q- 
/llq-/17p-)
5 6 5 10 3
Table 3.1: Characteristics of my patient cohort (n = 168)
The table show the number of patients who were male/female, whether they had 
been treated or not, what they VH gene mutation status was (Unmutated 
>98%/Mutated <98%), Binet stage, lymphocyte doubling time (LDT) (>12 
months/<12months) and any cytogenetics present.
3.1 CD38 expression as a surrogate marker of Vh gene mutation status
Damle et al (1999) not only identified Vh gene mutational status as a 
prognostic marker in CLL but also suggested that the 30% threshold for 
CD38 expression could be used as a surrogate marker for identifying 
patients with an unmutated VH gene profile. Since then this assertion has 
been questioned (Ghia et al 2003;Hamblin et al 2002;Ibrahim et al 2001). 
Therefore, in this study, we investigated the relationship between VH gene 
status and CD38 expression using the previously described cut-off levels 
(7%, 20% and 30%) in a cohort of 125 patients with at least 7% CD38 
expression and for whom VH gene mutation status was available. The VH 
gene status was determined using the method described previously
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(Matthews et al. 2004) and Vh gene sequences were compared to the 
nearest germ line sequence on the Igblast website 
(http://www.ncbi.nlm.nih.gov/igblast/). CD38 expression was determined 
by three-colour flow cytometry (CD5-FITC/CD38-PE/CD19-APC).
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Figure 3.1: Comparison of the VH status of the patients at different CD38 
threshold levels.
The VH gene mutation status of 125 CD38+ patients (with at least 7% CD38 
expression) was analysed at each threshold level. All of the CD38 thresholds 
examined showed marked discordance with VH gene mutation status indicating 
that in this cohort at least, CD38 cannot be used as a reliable surrogate marker of 
VH gene mutation status.
In contrast to the findings of Damle et al (1999), at each defined threshold 
for CD38 expression there were a higher number of patients with mutated 
Vh genes. At the 7% threshold level, 125 patients were investigated and 79 
had mutated Vh genes and 46 had unmutated Vh genes. At the 20% 
threshold level 37 out of 90 patients (41%) had an unmutated profile and 
53 out of the 90 patients (59%) had a mutated profile. At the 30% threshold 
level out of the 77 patients investigated 35 had unmutated VH genes (45%) 
and 42 had mutated Vh genes (55%). Therefore, in this cohort of CLL 
patients CD38 was not a faithful surrogate marker for VH gene mutation 
status, as at each threshold level a significant number of patients with 
mutated Vh genes were positive for CD38 expression. 63% of the patients
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at the 7% threshold level had mutated Vh genes, 58% were mutated at the 
20% level and 55% o f the patients had mutated Vh genes at the 30% 
threshold level.
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Figure 3.2 (A) Correlation between CD38 and VH gene status (B) Discordance 
between CD38 and VH gene mutation status
VH gene mutation status was determined using the method previously described 
and compared to the nearest germline sequence and CD38 expression was 
determined by triple colour flow cytometry (CD5-FITC, CD38-PE and CD19- 
APC). There was a positive correlation between CD38 expression and VH gene 
mutation status although there was 30% discordance when looking at the arbitrary 
threshold levels (>30% expression of CD38 and > 98% VH gene sequence 
homology)
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Although none o f the CD38 cut-off levels tested in this study were shown 
to be predictive o f V h gene mutation status, when the entire cohort (n = 
283) was analysed regardless o f the CD38 status o f the patients (Figure
4.1 A) there was a positive correlation between the percentage o f CD38 
expression and Vh gene mutation status (P = 0.0007; r2 = 0.06). However, 
as shown in figure 4 . IB there was 30% discordance between these two 
prognostic markers when using the cut-off o f >30% for positive expression 
for CD38 and >98% for the cut-off for unmutated VH genes. 39 o f 182 
patients (21%) were CD38+ but had mutated VH genes and 16 o f 182 
patients (9%) had unmutated V H genes but were CD38'.
3.2 CD38 expression and prognosis
f F o r m a t te d :  French (France)
There have been suggestions that 30% (Damle et al 1999), 20% (Ibrahim et F ie ld  C o d e  c h a n g e d
[ F o r m a t te d :  French (France)
al 2001 \  7%j(Krober et al 2002\ or even any CD38 expressing cells (Ghia Fje|d Code Changed
F o r m a t te d :  French (France) 
F o r m a t te d :  French (France)
et al 2003) are the best thresholds for defining prognosis in CLL. To 
examine these thresholds in terms of predicting prognosis in our CLL F ie ld  C o d e  C h a n g e d
cohort analyses were performed using time to first treatment, progression- 
free survival and overall survival as end-points.
3.2.1 The threshold level for CD38 and Time to first treatment
The time to first treatment (TTFT) is a useful measure o f advancing disease 
in CLL as therapeutic intervention is only indicated following evidence of 
disease progression. Therefore, if  treatment is required early, then by
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definition, the disease is progressive and the patient is likely to have a 
poorer clinical outcome. In this study, the patient cohort (those with both 
CD38 expression data and TTFT data available, n = 267) was divided 
according to the three published cut-off levels for CD38 and the TTFT was 
plotted for each group using Kaplan Meier analysis. Figure 3.3 shows the 
Kaplan Meier curves for TTFT using (A) 7%, (B) 20% and (C) 30% CD38 
expression cut-off levels
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Figure 3.3: Time to first treatment for CD38+ and CD38' patients at the (A) 
7% (B) 20% and (C) 30% threshold levels
CD38 expression was determined by triple colour flow cytometry (CD5-FITC, 
CD38-PE and CD19-APC) and the TTFT was derived from a database of clinical 
information. The TTFT for each threshold level was plotted using Kaplan Meier 
analysis. The 7% threshold level showed the least statistical difference in TTFT 
between CD38+ and CD38‘ patients (P = 0.0018) and the 20% and 30% threshold 
levels showed the same statistical difference in TTFT between CD38+ and CD38' 
patients (P < 0.0001).
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In agreement with previous studies, all three threshold levels used (7%, 
20% and 30%) showed the CD38+ patients had a significantly shorter 
TTFT than the patients who did not express CD38 above the defined 
thresholds (Rosenwald et al. 2001). The 7% threshold showed the smallest 
statistical difference in TTFT between CD38+ and CD38' CLL patients (P 
= 0.0018). Statistically the 20% and 30% threshold levels showed the same 
difference between the TTFT for CD38+ and CD38' patients (P < 0.0001 
and P < 0.0001 respectively). However there was a difference between the 
median TTFT for the CD38+ and CD38' patients between these two cut-off 
levels. At the 30% cut-off level the CD38‘ patients had a median TTFT of 
5375 days (-14.7 yrs) and the CD38+ patients had a median TTFT of 1397 
days (-3.8 yrs) whereas at the 20% cut-off level the CD38' patients had a 
median TTFT of 6034 days (-16.5 yrs) and the CD38+ patients had a 
median TTFT of 1397 days (-3.8 yrs). As the 20% threshold showed the 
greatest difference in mean TTFT, this suggests that this threshold was 
superior to the 30% threshold even though their P values were the same.
3.2.2 The threshold level for CD38 and progression-free survival
Progression-free survival (PFS) is an alternative marker of activity of the 
disease. It can be used to define whether a patient has indolent or active 
disease. If a patient has progressive disease then usually they require early 
therapeutic intervention and have an inferior clinical outcome. Figure 3.3 
shows the Kaplan Meier curves for PFS using (A) 7%, (B) 20% and (C) 
30% CD38 expression cut-off levels.
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Figure 3.4: Progression-free survival for CD38+ and CD38" patients at (A) 
7% (B) 20% and (C) 30% threshold levels.
CD38 expression was determined by triple colour flow cytometry (CD5-FITC, 
CD38-PE and CD19-APC) and the PFS was derived from a database of clinical 
information. The PFS for each threshold level was plotted using Kaplan Meier 
analysis. The 7% threshold level showed the least statistical difference in PFS 
between CD38+ and CD38' patients (P = 0.0003) and the 20% and 30% threshold 
levels showed the same statistical difference in PFS between CD38+ and CD38' 
patients (P < 0.0001).
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CD38+ patients had a shorter PFS than patients who were CD38' at all three 
threshold levels. The difference in PFS for CD38+ and CD38' patients was 
statistically significant (P = 0.0003) at the 7% CD38 threshold level and 
was highly significantly different at the 20% and 30% CD38 threshold 
levels (P < 0.0001 and P < 0.0001 respectively). Table 3.2 shows the 
difference in median PFS between the three threshold levels.
CD38 threshold level
7% 20% 30%
CD38' Undefined Undefined 6034 days 
(~ 16.5 yrs)
CD38+ 2386 days 
(~ 6.5 yrs)
1682 days 
(~ 4.6 yrs)
1589 days 
(~ 4.4 yrs)
Table 3.2: The median PFS for CD38+ and CD38' patients at all three 
threshold levels (7%, 20% and 30%).
CD38 expression was determined by triple colour flow cytometry (CD5-FITC, 
CD38-PE and CD19-APC) and the median PFS was determined using Kaplan 
Meier analysis. Undefined means the median time to disease progression had not 
been reached and therefore a figure could not be given.
In two of the cut-off levels (7% and 20%) after 8265 days (22.6 years) the 
CD38' patients had not reached the median time to disease progression. 
The median PFS for the CD38+ patients at the 7% and 20% cut-off levels 
were 2386 days (~6.5 years) and 1682 days (-4.6 years) respectively. At 
the 30% threshold level the median time to disease progression was 6034 
days (16.5 years) for CD38' patients and 1589 days (4.4 years) for CD38+ 
patients.
68
Chapter 3
Both the 20% and 30% threhold level have the same statistical significance 
when investigating PFS but which threshold level is superior? The 30% 
threshold level showed the CD38+ patients had a worse prognosis with a 
mean PFS o f  4.4 years in comparison to the 20% threshold level where 
their PFS was 4.6 years. However, the CD38' patients had a better 
prognosis at the 20% threshold level as they had not reached the median 
PFS whereas at the 30% threshold level it was 16.5 years. This data 
indicates that the 20% threshold level was superior as it showed the 
greatest difference between the median PFS in CD38+ and CD38' patients 
and it appears that the patients with CD38 expression between 20% and 
30% caused this difference.
3.2.3 The threshold level for CD38 and Overall survival
Overall survival (OS) is the ultimate statistic in medicine! However, 
particularly in the context o f clinical trials in CLL this parameter is rarely 
measured because o f  the relatively long natural history o f  CLL in many 
patients. In this study CD38 expression was measured in archived material 
from patients that had died from CLL-related causes was used to increase 
the number o f events and allow meaningful OS analysis.
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Figure 3.5: Overall survival curves for CD38+ and CD38‘ patients at (A) 7% 
(B) 20% and (C) 30% threshold levels.
CD38 expression was determined by triple colour flow cytometry (CD5-FITC, 
CD38-PE and CD19-APC) and the OS was derived from our database of clinical 
information. The OS for each threshold level was plotted using Kaplan Meier 
analysis. The 7% threshold level showed an intermediate statistical difference in 
OS between CD38+ and CD38' patients (P = 0.006) and the 20% threshold level 
showed the greatest statistical difference between the OS of CD38+ and CD38' 
patients (P = 0.005) and 30% threshold levels showed the least statistical 
difference in OS between CD38+ and CD38' patients (P = 0.01).
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At the 7% and 20% threshold levels for CD38 expression the median 
survival time for the patients who were classified as CD38" was not 
reached after 8265 days (22.6 years). At the 30% threshold level the 
median survival time for the CD38' patients was 7437 days (~20.4 years). 
In contrast, the patients who were CD38+ had a median OS o f  4770 days 
(13.1 years) at the 7% threshold level, 4304 days (11.8 years) at the 20% 
threshold level and 4065 days (11.1 years) at 30% threshold level.
At all three threshold levels the CD38' patients survived for a significantly 
longer time than patients who were CD38+. The 20% threshold level was 
the most prognostic out o f the three cut-off levels with the greatest 
significance with regard to overall survival between the two groups (P = 
0.005).
3.2.4 Prognostic sub-groups defined by CD38 expression and VH gene 
mutation status
Hamblin et al (1999) and Damle et al (1999) showed that Vh gene 
mutation status was prognostic; those patients with unmutated Vh genes 
had a shorter overall survival than those patients with mutated V H genes. 
Subsequently, Rosenwald et al (2001) showed that patients with unmutated 
Vh genes also had a shorter time to first treatment than those patients with 
a mutated Vh genes. A  number o f  studies have suggested that additional 
prognostic information may be gained by analysing CD38 expression and 
Vh gene mutation status in combination (Bilous et al. 2005;Jelinek et al.
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2001). Therefore, the patient cohort was divided into four groups; CD38' / 
mutated Vh genes, CD38+ / mutated V h genes, CD38' /unmutated V h genes 
and CD38+ / unmutated Vh genes. Figure 3.6 shows that when CD38 
expression is analysed in conjunction with Vh gene status the sub-group o f  
patients with CD38+ / unmutated Vh genes have the shortest mean TTFT 
(250 days) and the CD38' / mutated patients have the longest mean TTFT 
(6034 days).
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Figure 3.6 Time to first treatment for the different mutational status and 
CD38 expression
VH gene mutation status was determined using the method previously described 
and compared to the nearest germline sequence and CD38 expression was 
determined using triple colour flow cytometry (CD5-FITC, CD38-PE and CD 19- 
APC). Patients were classed as unmutated if their Vh genes were > 98% 
homologous to the closest germline sequence and were classed as CD38+ if they 
had > 20% expression of the CD38 antigen. The mutated / CD38' sub-group had 
the longest time treatment-free and the unmutated I CD38+ sub-group had the 
shortest TTFT.
Importantly, CD38 separated the mutated group into 2 sub-groups and the 
unmutated group into 2 sub-groups. Despite the Kaplan Meier curves 
showing clear separation, there was no statistical difference between
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unmutated patients who expressed or did not express CD38 (P = 0.19). 
However, the numbers in both groups were relatively small and this may 
contribute to the lack of statistical significance. In contrast, patients who 
had a mutated profile and were CD38+ had a significantly shorter TTFT 
than the mutated patients who were CD38* (P < 0.0001).
Vh gene mutation status is a known prognostic marker in CLL but there are 
a group of patients who have mutated Vh genes but still have aggressive 
disease. The classic sub-group that fit this description are the VH 3-21 
segment usage group which invariably have poor prognosis but usually 
have mutated Vh genes (Fait et al. 2005;Ghia et al. 2005). As Vh 3-21 has 
been shown to be associated with poor prognosis in the mutated group (Fait 
et al 2005) this was investigated in this patient cohort. Seventeen patients 
were found to have Vh 3-21, 8 were mutated and CD38+ (47%), 6 were 
mutated and CD38' (35%), 1 was unmutated and CD38" (6%) and 2 were 
unmutated and CD38+ (12%). The high number of mutated and CD38+ 
patients with this Vh gene usage may provide another explanation for why 
this group has a shorter TTFT than the mutated and CD38' patients, 
although there was still a high number of patients with Vh 3-21 who were 
mutated and CD38*.
This data suggests that analysis of CD38 along with Vh gene mutational 
status can help to predict those patients with mutated Vh genes at risk of 
disease progression. Given that the patients with mutated Vh genes still had 
a shorter TTFT than the patients with unmutated Vh genes irrespective of 
their CD38 expression status (positive or negative), this suggests that
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individually, Vh gene mutation status is a superior prognostic marker than 
CD38 expression.
CD38 expression (£ / <20%)
CD38' CD38+
Mutated 6034 days (16.5 years) 2304 days (6.3 years)
Unmutated 680 days (1.9 years) 250 days (0.7 years)
Table 3.3 Median TTFT for each group.
VH gene mutation status was determined by the method described previously and 
then compared to the nearest germline sequence and patients with >98% 
homology were classed as unmutated. CD38 expression was determined by triple 
colour flow cytometry (CD5-FITC, CD38-PE and CD19-APC) and patients with 
> 20% CD38 expression were classed as positive. Patients who were mutated / 
CD38' had the longest median TTFT (16.5 years) and patients who were 
unmutated / CD38+ had the shortest median TTFT (0.7 years).
The median TTFT also separates the mutated and unmutated into 2 groups 
giving four groups in total. The patients who had mutated Vh genes and 
were CD38' had a median TTFT of 6034 days (16.5 years) whereas the 
patients who had mutated VH genes and were CD38+ had a median TTFT 
of 2304 days (6.3 years). The TTFT for patients with unmutated Vh genes 
and were CD38‘ was 680 days (1.9 years) and the TTFT patients with 
unmutated Vh genes and CD38+ was 250 days (0.7 years). Taken together, 
this data suggests that the Vh gene mutation status of the patient is a more 
important determinant of TTFT than CD38 expression. However, the 
integration of these two parameters creates a hierarchy of risk that 
separates patients into four distinct categories. This approach could be used 
in the future to more accurately inform clinicians and patients about the 
likely course of an individual’s disease.
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3.3 Does CD38 expression change over time?
There has been great controversy over whether CD38 expression changes 
over the course of the disease and/or after treatment; Hamblin et al ( 2002) 
suggested that CD38 expression does change over time whereas Ibrahim et 
al ( 2001) argued that expression of CD38 remains fairly constant 
throughout the course of the disease. To investigate these contradictory 
claims, samples from individual patients were taken at different time points 
over the course of this study. A total of 21 patients were serially 
investigated; at least three measurements of CD38 expression were made 
for each patient at various time intervals (1 month -  24 months). Statistical 
analysis was carried out using analysis of variance (ANOVA) to establish 
whether the intra-patient variation in CD38 expression was significant.
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Figure 3.7 Longitudinal analysis of CD38 expression in 21 patients.
CD38 expression was analysed in 21 patients at different time points throughout 
the investigation. Only patients with 3 or more time points were included in the 
study so that statistical analysis could be carried out. An ANOVA test showed no 
significant change in CD38 expression over time (P = 0.3).
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The intra-patient CD38 expression did vary to some extent over time (1% - 
27%). However the ANOVA test showed no significant change in CD38 
expression (P = 0.3). One out of 21 patients investigated (9.5%) crossed the 
20% CD38 threshold thereby changing their CD38 status from negative to 
positive. This may be due to the fact that this patient had CD38 expression 
near the 20% threshold and so slight fluctuations in their CD38 expression 
pushed them over the threshold. This might be due to a number of factors 
including experimental error in the measurement of CD38 expression and 
intrinsic variation in numbers of circulating CD38+ CLL cells. This 
indicates a problem in the arbitrary cut-off system currently employed as 
although both patients changed from being classed as CD38’ to being 
CD38+ their disease did not change and neither patient showed disease 
progression over the period of the study.
3.4 ZAP-70 expression and CD38 expression
Zeta associated protein-70 (ZAP-70) is a protein tyrosine kinase that has 
been shown to be an important prognostic marker in CLL (Orchard et al.
2004) and Rassenti et al also suggested that it was more prognostic than Vh 
gene mutational status (Rassenti et al. 2004). ZAP-70 was first identified as 
being important in CLL following micro-array studies comparing Vh gene 
mutated and unmutated CLL samples (Rosenwald et al 2001). 
Consequently, it has also been suggested as a surrogate marker for Vh gene 
mutation status. Furthermore, Wiestner et al (Wiestner 2005) suggested 
that when investigating TTFT, ZAP-70 is a superior prognostic marker
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when compared to Vh gene mutation status and CD38 expression. To 
determine whether our data agreed with this suggestion, ZAP-70 was 
investigated in relation to CD38 and Vh gene status. Cells were triple 
labelled with ZAP-70-Alexa fluor 488, CD38-PE and CD19-APC. The 
percentage of cells expressing ZAP-70 and CD38 were derived from gated 
histogram plots using the CD 19' population to define the lower limit of 
positivity for ZAP-70 expression and using a conventional isotype control 
method for determining the percentage of CLL cells that were CD38 
positive.
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Figure 3.8 (A) Correlation between CD38 and ZAP-70 (B) Discordance 
between CD38 and ZAP-70 using a 20% threshold for both parameters.
CD38 expression and ZAP-70 expression was determined by triple colour flow 
cytometry (ZAP-70-Alexa fluor 488, CD38-PE and CD19-APC) on fixed and 
permeabilised cells. There was a positive correlation between CD38 and ZAP-70 
expression although there was 40% discordance when investigating the arbitrary 
threshold levels (>20% expression of both CD38 and ZAP-70)
CD38 and ZAP-70 were positively correlated (P < 0.0001; r2 =0.1) but 
again there was discordance between the two parameters (40% 
discordance). Using >20% cut-off for positive expression of CD38 and 
>20% for positive expression o f ZAP-70, 16% o f patients (52 out o f 327)
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were CD38+ but ZAP-70', and 24% of patients (77 out of 327) were CD38' 
but ZAP-70+.
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Figure 3.9 (A) Correlation between ZAP-70 and VH gene status (B) 
Discordance between ZAP-70 and VH gene status using a 20% threshold for 
ZAP-70 and a 2% threshold for VH gene mutation status.
VH gene mutation status was determined using the method previously described 
and compared to the nearest germline sequence and ZAP-70 expression was 
determined by two colour flow cytometry (ZAP-70-Alexa fluor 488 and CD 19- 
APC). There was a positive correlation between VH gene mutation status and 
ZAP-70 expression although there was 43% discordance when investigating the 
arbitrary threshold levels (>98% VH gene sequence and >20% ZAP-70 
expression)
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ZAP-70 expression was positively correlated with Vh gene mutation status 
(P = 0.0042; r2 = 0.027). There was however 43% discordance between the 
two prognostic markers. Using >98% cut-off for unmutated Vh gene 
mutation status and >20% cut-off for positive expression of ZAP-70, 38% 
of the patients (118 out of 309) were ZAP-70 positive but had mutated Vh 
genes and 5% of the patients (16 out of 309) were ZAP-70 negative but had 
unmutated Vh genes. Within the cohort ZAP-70 was found to be 
prognostic when comparing ZAP-70 and TTFT (P = 0.026), ZAP-70 and 
PFS (P = 0.017) and ZAP-70 and OS (P = 0.0008) (Unpublished data).
3.5 Clinical factors and CD38
Clinical factors are also important in determining the prognosis of the CLL 
patient. Lymphocyte doubling time (LDT), Binet stage at diagnosis and 
cytogenetics are all important markers used at present within the clinic. 
These markers typically indicate how aggressive the disease is but they are 
not useful as prospective markers to predict disease progression. This study 
set out to investigate the relationship between CD38 expression and other 
commonly used clinical parameters. Lymphocyte doubling time (LDT) was 
split into 2 groups for the analysis; the patients who had a LDT <12 and the 
patients who had a LDT >12 as these are the parameters used in the clinical 
practice (Shanafelt, Geyer, & Kay 2004).
80
Chapter 3
P = 0.02
100n
(A
I  80* 
2- 60-
40-
20 -
>12<12
CD38-
CD38+
LDT
Figure 3.10. The number of CD38+ and CD38' patients based on their LDT.
175 patients were analysed for CD38 expression using triple colour flow 
cytometry (CD5-FITC, CD38-PE and CD19-APC) and lymphocyte doubling time 
(LDT) was determined using a clinical database. A Fisher’s exact test was carried 
out and CD38 expression was associated with <12 months LDT.
Out o f the 23 patients with a LDT <12, 9 patients (39%) were CD38' and
14 (61%) were CD38+. 99 patients (65%) out o f 152 had a LDT >12 and
were CD38' whereas there were 53 patients (35%) out o f 152 who were
CD38+ and had a LDT >12. There was a significantly higher proportion o f
CD38+ patients with a LDT o f less than 12 months and a higher proportion
o f CD38' patients with a LDT greater than 12 months (P = 0.02).
The Binet staging system was split into 2 groups for this analysis; Binet 
stage A (good prognosis) and Binet stage B/C (poor prognosis) (Binet et al. 
1981)
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Figure 3.11 The number of CD38+ and CD38' patients in Binet Stage A and 
Binet Stages B/C
240 patients were analysed for CD38 expression using triple colour flow 
cytometry (CD5-FITC, CD38-PE and CD19-APC) and Binet stage was 
determined from a clinical database. The Binet staging system was split into 2 
groups for this analysis; Binet stage A (good prognosis) and Binet stage B/C (poor 
prognosis). A Fisher’s exact test was carried out and CD38 expression was found 
to be associated with Binet stages B/C.
140 patients were CD38' and 118 of these patients (84%) were in Binet 
Stage A and 22 patients (16%) were in Binet stages B/C. Out of the 100 
patients that were CD38+ 67 patients (67%) were Binet stage A and 33 
patients (33%) were Binet stages B/C. There was a significantly higher 
proportion of CD38+ patients in Binet Stage B/C and a significantly higher 
proportion of CD38' patients in Binet Stage A (P = 0.0005).
The cytogenetic abnormalities described within the patient cohort were 
categorised into 3 groups; the good prognostic cytogenetic group contained 
the normal karyotype (i.e. no cytogenetic lesion detected by fluorescence in 
situ hybridisation) and 13ql4 deletion (Mehes 2005), the intermediate 
prognostic cytogenetic risk group contained trisomy 12 and 6q deletion 
(Cuneo et al. 2004;Mehes 2005) and the poor prognostic cytogenetic risk
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group contained 17 deletion, llq  deletion and complex karyotype (Mehes
2005).
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Figure 3.12 Cytogenetics of CD38+ and CD38" patients
168 patients were analysed for CD38 expression and cytogenetic abnormalities. 
CD38 expression was determined by triple colour flow cytometry (CD5-FITC, 
CD38-PE and CD19-APC) and the cytogenetic abnormalities were determined 
from a clinical database. The abnormalities were split into 3 groups; good risk 
(normal/13q 14), intermediate risk (trisomy 12/6q‘) and poor risk (17p71 lq* 
/complex) prognostic groups. A Chi Squared test was carried out to analyse CD38 
expression and the three prognostic cytogenetic risk groups. CD38 expression was 
associated with the intermediate and poor prognostic cytogenetic groups.
89 patients were classified as CD38' and 79 of these patients (88%) were in 
the good prognosis cytogenetics risk group, 5 patients (6%) had the 
intermediate prognosis cytogenetics and 5 patients (6%) had the poor 
prognosis cytogenetics. 71 patients were CD38+ and 38 of these patients 
(54%) had the good prognosis cytogenetics, 8 patients (11%) had the 
intermediate prognosis cytogenetics and 25 patients (35%) had the poor 
prognosis cytogenetics. There were a greater proportion of CD38‘ cells 
with a normal karyotype or the good prognosis cytogenetic marker 13ql4 
whereas a greater proportion of CD38+ patients had the poor cytogenetic 
markers 17p deletion and llq  deletion (P < 0.0001).
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3.6 Conclusion
In this investigation CD38 expression was not found to be a reliable 
surrogate marker for Vh gene mutation status at any of the thresholds tested 
(7%, 20% and 30%). Although CD38 expression correlated with Vh gene 
mutation status there was a significant degree of discordance between the 
two parameters with some CD38+ patients having mutated VH genes and 
some CD38‘ patients having unmutated Vh genes. The 30% threshold level 
for CD38 expression showed the greatest concordance with Vh gene 
mutation status but even this threshold showed significant discordance 
between the two parameters. These findings were in agreement with 
Krober et al ( 2002) who showed that 30% of the patients within this study 
were discordant for CD38 expression and Vh gene mutation status.
The threshold for defining CD38 status with the greatest prognostic value 
was 20% expression and this was demonstrated by significant differences 
in TTFT (P < 0.0001), PFS (P < 0.0001), and OS (P = 0.005) between 
CD38+ and CD38' patients. The CD38+ patients had a significantly shorter 
TTFT, a significantly shorter PFS and a significantly shorter OS. This was 
in agreement with an earlier study by Ibrahim et al (2001) who investigated 
218 CLL patients and also found the 20% threshold for CD38 expression 
was the most prognostic. This data indicates that patients who express 
CD38 have a more aggressive and progressive disease (as shown by PFS 
data), a higher probability of requiring early treatment intervention (as 
shown by the TTFT data) and a shorter survival (as shown by the OS data).
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Vh gene mutation status is a known prognostic marker in CLL but there are 
a group of patients who have mutated Vh genes but still have aggressive 
disease. The classic sub-group that fit this description are the VH 3-21 
segment usage group which invariably have poor prognosis but usually 
have mutated Vh genes (Fait et al 2005;Ghia et al 2005). As Vh 3-21 has 
been shown to be associated with poor prognosis in the mutated group (Fait 
et al 2005) this was investigated in this patient cohort. The high number of 
mutated and CD38+ patients with this VH gene usage (8 out of the 17 
patients; 47%) may provide another explanation to why this group has a 
shorter time to first treatment than the mutated and CD38' patients, 
although there was still a high number of patients with Vh 3-21 who were 
mutated and CD38'. This data implies that the combination of CD38 and 
Vh gene status is required for a more accurate clinical assessment, as this 
would help to identify the patients with mutated Vh gene who will have 
progressive disease and may require treatment. The data in this study 
shows when looking at Vh gene status and the CD38 expression is included 
the cohort can be split into four sub-groups. The patients with mutated Vh 
genes that also expressed CD38 (>20%) had a shorter TTFT than patients 
with mutated VH genes that did not express CD38 (<20%). Interestingly, 
VH gene mutation status appeared to be more important than CD38 
expression in determining TTFT as patients with unmutated Vh genes had 
a shorter TTFT than patients with mutated Vh genes. However, the 
unmutated patients could also be split into 2 groups based on CD38 
expression; patients with unmutated Vh genes and CD38+ patients having 
the shortest TTFT.
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The longitudinal data generated in this study indicated the CD38 
expression does not change significantly over time which was in agreement 
with Ibrahim et al (2001) but in disagreement with Hamblin et al (2002) 
and Oscier et al ( 2002). Although CD38 expression did not change 
significantly over time, 1 out of the 21 patients did cross the 20% threshold 
barrier changing their CD38 status from negative to positive. This may be 
due to the fact that this patient had CD38 expression near the 20% 
threshold and so slight fluctuations in their CD38 expression pushed them 
over the threshold. This might be due to a number of factors including 
experimental error in the measurement of CD38 expression and intrinsic 
variation in numbers of circulating CD38+ CLL cells. This indicates a 
problem in the arbitrary cut-off system currently employed as although 
both patients changed from being classed as CD38' to being CD38+ their 
disease did not change and neither patient showed disease progression over 
the period of the study.
None of the patients investigated in this longitudinal study had received 
treatment within 3 months of the study. Krober et al (2002) found that 
treatment induced variations in CD38 expression. This is an area that 
would have to be investigated within this CLL cohort in the future.
There was a correlation between CD38 expression and the other well 
known prognostic markers in CLL, VH gene mutation status and ZAP-70 
expression. In agreement with Wiestner et al (2003) ZAP-70 also 
correlated with Vh gene mutation status. This suggests that analysis of all 3
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prognostic markers, Vh gene status, CD38 and ZAP-70, would be more 
informative to the clinician of the patient’s prognosis than any one marker 
in isolation. The discordance between the three prognostic markers 
highlights the problems when using arbitrary thresholds for defining 
positive or negative status. The data in this study suggests that each 
prognostic marker should be regarded as a continuous variable to provide 
more information to the clinician.
CD38 expression was associated with Binet Stage B/C, a lymphocyte 
doubling time of <12 and the cytogenetic abnormalities 17p deletion (p53 
mutation) and llq- (mutation of the ATM gene). All of these factors are 
indicative of aggressive disease with poor clinical outcome (Mehes 
2005;Shanafelt, Geyer, & Kay 2004) which strengthens the idea that CD38 
expression is a poor prognostic marker in CLL.
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Chapter 4: Microarray analysis of CD38+ and CD38' cells derived 
from the same patient.
CD38 is an important prognostic marker in CLL (Ghia et al. 2003;Hamblin 
et al. 2002), but to-date there is no biological rationale for the association 
between CD38 and poor prognosis. In order to address this issue directly, 
an investigation of the transcriptional signatures of purified CD38+ and 
CD38‘ cells derived from the same patient was carried out.
Aims: To investigate whether CD38+ cells have a different transcriptional 
signature to their CD38' counterparts.
Hypothesis: CD38+ cells will have a differential transcriptional signature to 
their CD38' counterparts.
CD38+ and CD38' cells were physically cell sorted from samples derived 
from individual patients using a MoFlo high speed cell sorter. This 
approach ensured that downstream microarray experiments were performed 
on highly purified (>98%) sub-populations of CLL cells. In this way, the 
intrinsic inter-patient variation in global gene expression would be negated 
and the risk of contamination of the CLL cell gene signature by other 
peripheral blood mononuclear cells was effectively eliminated.
To determine the characteristics of the cell sorted sub-populations, their 
light chain expression and Vh gene sequences were investigated. Light
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chain restriction was measured by flow cytometry. Percentage Vh gene 
sequence homology to the closest germline sequence and Vh gene segment 
usage was determined by DNA analysis using the previously described 
BIOMED-2 Standardized Primers and Protocols (Matthews et al. 2004) 
followed by direct sequence analysis using Igblast 
(http://www.ncbi.nlm.nih.gov/igblast/) of amplified DNA derived from the 
same patient’s sorted CD38+ and CD38‘ sub-populations. The paired 
CD38+ and CD38' cells from each patient showed the same light chain 
restriction i.e. they expressed either k  or X light chains and therefore the 
cells were deemed monotypic. In addition, the paired CD38+ and CD38' 
cells from each patient had identical Vh gene sequences and were therefore 
monoclonal (Table 4.1). This indicated that, at least in this limited cohort, 
the CD38+ and CD38' cells derived from the same patient were derived 
from a single clone that had undergone a malignant transformation and the 
only detectable difference between them was the absence or presence of the 
expression of the CD38 antigen.
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Patient # Light chain restriction
% sequence homology 
and VH gene usage
CD38+ CD38 CD38+ CD38
1 X X 98% (1-69) 98% (1-69)
2 K K 94% (4-34) 94% (4-34)
3 X X 95% (3-21) 95% (3-21)
4 X X 91% (3-23) 91% (3-23)
5 K K 89% (4-59) 89% (4-59)
6 X X 99% (3-72) 99% (3-72)
7 K K 100% (1-18) 100% (1-18)
8 X X 99% (2-70) 99% (2-70)
Table 4.1: Light chain restriction and sequence homology for 8 patients with 
bimodal expression of CD38
For each patient the light chain restriction was investigated by flow cytometry and 
was found to be the same for both CD38+ and CD38' cells. In addition, the paired 
CD38+ and CD38' cells had identical VH gene sequences thereby revealing their 
monoclonal pedigree.
Microarray analyses were carried out using U133A gene chipsets which 
contain 22,283 human gene sets (Agilent technologies 2006). Highly 
purified (>98%) CD38+ and CD38‘ cells were analysed on separate gene 
chips. Prior to individual gene analysis, a global normalization technique 
was employed which involved the determination of the mean gene 
expression on each chip and this value was used as the denominator to 
produce a normalized value for each gene. This was followed by 
normalization for each gene in all the samples. The median value was 
determined for each gene and then for each sample the gene expression 
was divided by the median value. There are many techniques for analysing 
microarray results, for example, Statistical tests such as ANOVA (analysis 
of variance) and /-tests and SAM (significance analysis of microarray) 
analysis (Gale et al. 2005;Tusher, Tibshirani, & Chu 2001). In this study,
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the results were analysed using Genespring software (Agilent 
Technologies) and two different methods of analysis were employed. The 
first method used two statistical tests; ANOVA and the student’s /-test. The 
second method used a technique specifically designed for microarray 
analysis called SAM.
4.1 Statistical Method 1 (SMI)
Any genes that were not present or deemed marginal (Affymetrix 2006) in 
at least one of the samples (15122 genes remained) as employed by Gale et 
al ( 2005), or genes that did not have a > 2 fold difference in transcription 
between CD38+ and CD38' subsets derived from the same patient were 
removed from the gene list (1383 genes remained) as per the method 
previously used by Schmelz et al ( 2005) and Huttmann et al ( 2006).
An ANOVA was carried out followed by a Student’s /-test on the 
remaining 131 genes. For both tests P < 0.05 was considered to be 
statistically significant, differences in gene transcription with P values 
greater than 0.05 were removed from the subsequent gene list. The 62 
genes that remained following this process are shown in the gene cluster 
heat map in figure 4.2. A red colour denotes genes that were relatively 
highly expressed in CD38+ CLL cells and a green colour represent genes 
that were relatively under expressed in CD38+ CLL cells when compared 
with their CD38‘ counter-parts. The CD38+ samples clustered together and 
the CD38’ samples clustered together suggesting that the gene transcription
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signature associated with the expression o f  the CD38 antigen was 
consistent between patients. The raw data from these analyses can be found 
via the internet (http://w w w .ncbi.nlm.nih. gov/geo/) with the follow ing  
accession numbers: GSM 146300-G SM 146335.
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Figure 4.1 Gene cluster heat map showing the final 62 genes that are 
differentially expressed between CD38+ and CD38' cells from the same 
patient.
The heat map showed that the CD38+ and CD38' samples clustered together and 
expressed a relatively consistent differential gene expression profile. The red 
represents genes that were relatively highly expressed and the green represents 
genes that were relatively under expressed in CD38+ CLL cells when compared 
with CD38' cells derived from the same patient.
4.2 Statistical Method 2 (SM2)
All the genes that were not present or deem ed marginal in at least one o f  
the samples were removed from the gene list (15122 genes remained). The 
remaining genes were analysed using SAM  (significance analysis o f
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microarray) which was employed by Huttmann et al ( 2006). This method 
was specifically designed for microarray analysis (Tusher, Tibshirani, & 
Chu 2001). In contrast to SMI, SAM analyses all the genes and designates 
a threshold level at which the differences in gene transcription are deemed 
significant (Tusher, Tibshirani, & Chu 2001). In this study the threshold 
level was P <0.05. After SAM analysis 467 genes remained (Figure 4.2)
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Figure 4.2 Gene expression profiling of CD38+ and CD38' cells derived from 
the same patient
467 genes were differentially expressed between the CD38+ and CD38' sub-clones 
derived from the same patient. The red represents genes that were relatively 
highly expressed and the green represents genes that were relatively under­
expressed in CD38+ CLL cells when compared with paired CD38' CLL cells.
In accordance with SMI, the samples revealed a clear gene expression 
pattern with the CD38+ samples clustering together and the CD38* samples 
clustering together. However, following SAM analysis 467 genes were
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considered to be differentially expressed between the CD38+ and CD38 
sub-clones derived from the same patient.
4.3 Comparison of Statistical Methods 1 and 2
The genes that were not present in at least one of the samples or were 
deemed marginal were removed from the gene list before carrying out both 
SMI and SM2. In SMI an addition filtering step was added to remove 
genes that had less than a two fold change in transcription between CD38+ 
and CD38' samples; a method previous employed by a number of other 
research groups (Huttmann et al. 2006;Schmelz et al. 2005). This removed 
some of the genes from the gene list derived from SMI that were present 
following analysis using SM2. In SMI an ANOVA was carried out 
followed by a student’s /-test. The ANOVA analysed the variance between 
all the genes and the /-test then investigated the difference between the 
CD38+ and CD38‘ genes. In SM2 SAM analysis was carried out which 
looked at the genes and determines a threshold at which the genes are 
deemed significant. After SMI 62 genes were differentially expressed 
between the CD38+ and CD38" sub-clones whereas 467 genes were 
differentially expressed in CD38+ and CD38’ sub-clones after SM2. The 
first method appears more stringent as the genes had to pass two P < 0.05 
filters and consequently fewer genes were present after the analyses. Out of 
the 62 genes that were present after SMI, 61 genes were also found in the
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list of 467 genes after SM2. The one gene missing from SM2 (but present 
in SMI) had very significant individual P-values for patients #2 and #3 
which allowed it to pass the ANOVA and Student’s Mest filters but since 
SAM uses different algorithms, the highly non-significant individual P- 
values for patients #1, #4, #5 and #6 did not allow this gene (thromboxane 
A2 receptor isoform 2) to pass its significance threshold. The question 
remains as to whether the genes missing from SM1 (but present in SM2), 
or the gene in SMI (but missing from SM2) are biologically significant? 
However, this question was not addressed in this present study due to time 
constraints.
131 genes 4.72005 genes common m 2 tests and 2 fold change
406
21748 
al genes
Flter on Foti Change
Figure 4.3 Venn diagram showing the comparison of the genes that were 
present after SMI and SM2.
The red circle shows the 131 genes that were present after the ANOVA in SMI. 
The green circle shows the 62 genes that were present after the ANOVA and the 
student’s t test (SMI) and the blue circle shows the 467 genes that were present 
after SAM analysis (SM2). The intersection of the three circles reveals that 61 
genes were common to both the SMI and SM2 analyses.
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4.4 Pathway Architect
The gene list containing the 61 genes present after both statistical methods 
was exported to the software programme called Pathway Architect 1.1.0 
(Stratagene). Two pathways were drawn; a pathway using all the genes 
relatively over-expressed in the CD38+ cells (Figure 4.5A) and a pathway 
using all the genes that were relatively over-expressed in the CD38' cells 
(Figure 4.5B). Pathway Architect performs a literature review on the 
imported gene list via Pubmed (http://www.ncbi.nlm.nih.uov/Pubmed ) and 
using this information draws an appropriate pathway. The arrows represent 
genes that are directly associated with one another either by activation, de­
activation or via a protein complex (given in Figure 4.4 legend).
CD38 was found within the list of genes highly expressed in the CD38+ 
cells and was reassuringly absent from the list of genes highly expressed in 
the CD38* cells. CD38 gene transcription was significantly higher in the 
CD38+ cells (mean fold change; 9.1) compared to their CD38' counter­
parts. This served as a good internal control for the efficacy of the cell 
sorting technique (Figure 4.4).
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Figure 4.4 Diagram showing the expression levels of CD38 in the CD38+ and 
CD38' samples from each of the patients.
In each case CD38 gene transcription was significantly higher in the CD38+ 
sample (on the left) when compared to the paired CD38' sample (on the right) for 
each patient. This finding confirms the success of the cell sorting procedure and 
shows the relative consistency of the gene expression differences between CD38+ 
and CD38" CLL cells derived from different patients.
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Figure 4.5A Pathway produced from the genes highly expressed in the CD38+ 
cells when compared to their CD38' counter-parts
CD38+ and CD38' cells from the same patient were analysed by microarray. The 
gene list produced after SMI and SM2 was imported into Pathway Architect and 
the genes that were relatively over-expressed in the CD38+ cells were analysed for 
direct associations. This was achieved by interrogating PubMed 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed). Subsequently, a pathway 
with the genes that were directly associated with one another was produced.The 
significance o f the colours and shapes are described in the theme legend.
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Figure 4.5B Pathway produced from the genes highly expressed in the CD38‘ 
cells when compared to their CD38+ counter-parts
CD38+ and CD38" cells from the same patient were analysed by microarray. The 
gene list produced after SMI and SM2 was imported into Pathway Architect and 
the genes that were relatively over-expressed in the CD38' cells were analysed for 
direct associations. This was achieved by interrogating PubMed 
(http ://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMedV Subsequently, a pathway 
with the genes that were directly associated with one another was produced.The 
significance of the colours and shapes are described in the theme legend.
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The genes that were relatively up-regulated in CD38" cells were not 
investigated further in this study due to time constraints. Instead, it was 
decided to focus the investigation on genes that were relatively over­
expressed in the CD38+ cells. This decision was based on the fact that there 
appeared to be a larger number of directly associated genes that were 
relatively over-expressed in CD38+ CLL cells. It seemed likely that these 
genes contribute to the inferior prognosis associated with CD38 expression 
in CLL.
There appeared to be ‘epicentres’ within the pathway derived from the 
genes that were relatively up-regulated in the CD38+ cells; one around 
vascular endothelial growth factor (VEGF), a second around CCL3 and one 
around interleukin-lp (IL-lp). This suggested that these three genes were 
either involved in the control of these associated genes or were being 
regulated by these genes.
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Figure 4.6: Diagram showing the expression levels of (A) VEGF and (B) IL- 
ip in the CD38+ and CD38' paired samples from each of the patients.
In every case VEGF and IL-ip were relatively over-expressed in the CD38+ 
samples (on the left) when compared to the paired CD38" samples (on the right).
VEGF has been associated with tumour vascularisation in the bone marrow 
of CLL patients and has been shown to be expressed at high concentrations 
in some CLL cells. (Ferrajoli et al. 2001). In this regard, McCabe et al (
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2004) also suggested a link between CD38 expression and VEGF 
expression levels. IL -lp  is w ell known to be associated with VEGF along 
with the cytokines CXCL2 and CCL3 (Saijo et al. 2002). These four genes 
were o f  particular interest due to the connections already made between  
these genes and CLL, and they were found to be highly expressed in the 
C D38+ cells; VEGF (mean fold change; 5.8. 14/62 genes from SMI gene 
list and 15/467 genes from SM2 gene list), IL-1 (3 (mean fold change; 4.1. 
21/62 from SMI gene list and 36/467 genes from SM2 gene list), CXCL2 
(mean fold change; 9.4. 3/62 from SMI gene list, 3/467 genes from SM2 
gene list), and C C L 3/M IP-la (mean fold change; 5.4. 16/62 from SMI 
gene list and 17/467 genes from SM2 gene list). These four genes were 
found to be directly associated as shown in Figure 4.7.
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Figure 4.7: Pathway showing the direct interaction between these 4 genes.
This pathway was derived from Pathway Architect showing the direct interactions 
between VEGF, IL-1 (3, CXCL2 and CCL3. These four genes were highly 
expressed in the CD38+ sub-clones when compared to their CD38' counter-parts. 
The significance o f the colour of the shapes and lines is described in the theme 
legend.
Akt and ZAP-70 were also found to be highly expressed in C D 38+ cells 
when compared to CD38‘ cells; Akt (mean fold change; 2.5. 139/467 from
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SM2 gene list) and ZAP-70 (mean fold change; 2.2. 214/467 from SM2 
gene list). Akt is up-regulated in CLL cells and is associated with 
resistance to apoptosis (Hay 2005) and its reported constitutive activation 
in CLL cells (Cuni et al. 2004) encouraged a more thorough investigation 
of its expression in CD38+ CLL cells. ZAP-70, an important prognostic 
marker in CLL (Rassenti et al. 2004), was also shown to be relatively over­
expressed in CD38+ CLL cells. This again encouraged further 
investigation.
4.5 Protein Validation
4.5.1 Analysis of VEGF, IL-lp, Akt in paired CD38+ and CD38 
samples
VEGF, IL-1 p and Akt were up-regulated at the level of transcription in the 
CD38+ cells when compared to their CD38' counter-parts derived from the 
same patient, but was this true at the protein level? The expression levels of 
VEGF, IL-1 (3 and Akt were investigated by three colour flow cytometry in 
CLL patients with bimodal expression of CD38 (including all 6 patients 
that were used in the microarray experiments).
There was a wide range of expression of VEGF, IL-1 p and Akt in CD38+ 
and CD38' samples derived from the same patient. The level of expression 
of VEGF ranged from 38.5 -  244.8 mean fluorescence intensity (MFI) 
units, IL-1 p ranged from 6.1 -  41.6 MFI units and Akt ranged from 61.3 -
276.2 MFI units. Using paired Student’s /-test analyses, the expression of
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VEGF, IL-lp and Akt were all found to be significantly higher in CD38+ 
cells when compared to CD38' cells derived from the same patient (P < 
0.0001, P = 0.0002 and P < 0.0001 respectively).
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Figure 4.8 Protein expression in CD38+ and CD38' cells derived from the 
same patient
CD38+ and CD38' cells from patients with bimodal expression of CD38 were 
investigated for (A) VEGF expression (B) IL-1 (3 expression and (C) Akt 
expression by flow cytometry. In each case the CD38+ cells had significantly 
higher protein expression than their CD38' counter-parts as determined by paired 
Student’s Mest. The horizontal lines in each plot denote the median value for each 
cell population.
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4.5.2 ZAP-70 analysis in CD38+ and CD38" sub-clones derived from the 
same patient
ZAP-70 gene transcription was found to be relatively over-expressed in the 
CD38+ cells when compared to their CD38" counter-parts. ZAP-70 is an 
important prognostic marker within CLL and its expression is associated 
with poor prognosis and shorter overall survival than patients with no ZAP- 
70 expression (Schroers et al. 2005;Wiestner et al. 2003). It has also been 
shown that ZAP-70 is associated with activated B-cells and cells 
containing ZAP-70 have the ability to signal more effectively via the BCR 
(Chen et al. 2006). ZAP-70 expression was investigated in CD38+ and 
CD38" cells derived from 36 individual CLL patients by triple colour flow 
cytometry (ZAP-70-Alexa fluor 488, CD38-PE and CD19-APC). Regions 
were drawn around the CD38+ and CD38‘ CLL cells and these regions 
were forward gated into CD19/ZAP-70 dot plots.
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Figure 4.9: ZAP-70 expression in CD38+ and CD38' cells from 3 bimodal 
CLL patients (Pepper et al. 2006)
CLL patients with bimodal expression o f  CD38 showed differential expression o f 
ZAP-70 in CD38+ (R3 gated cells in pink/red/green) and CD38" (R2 gated cells in 
blue and mauve) cells derived from the same patient irrespective o f their 
percentage CD38 expression or their ZAP-70 status.
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CD38* cells showed significantly higher expression of ZAP-70 when 
compared to their CD38' counter-parts. This was not dependent on the size 
of the CD3 8-expressing clone or the ZAP-70 status of the patient (whether 
they were positive (> 20% expression) or negative (< 20% expression)).
4.6 Conclusion
CD38 expression has been associated with poor prognosis in CLL (Ghia, 
Guida, Stella, Gottardi, Geuna, Strola, Scielzo, & Caligaris-Cappio 
2003;Hamblin, Orchard, Ibbotson, Davis, Thomas, Stevenson, & Oscier 
2002;Ibrahim et al. 2001) but to-date there is no biological rationale to 
explain this phenomenon. CD38+ and CD38' cells derived from the same 
patient were analysed by microarray and were found to have characteristic 
differential gene expression profiles.
Light chain restriction and Vh gene mutation status and Vh gene segment 
usage was analysed in the CD38+ and CD38' sub-groups. CD38+ and 
CD38" cells had the same light chain restriction (either K or X) and had the 
same Vh gene mutation status and the same Vh gene segment usage 
indicating the cells were monoclonal. This suggests that the CD38+ and 
CD38’ cells in this study were not derived from two separate transforming 
events (i.e. biclonal disease) but rather from a disease with a single cell of 
origin.
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In agreement with McCabe et al ( 2004) VEGF expression was associated 
with CD38 expression in this study. It has been shown that VEGF 
signalling through the VEGFR2 receptor results in activation of the 
PI3K/Akt pathway which is a cell survival pathway (Bairey et al. 2004). 
Since VEGF, VEGFR2 and Akt were all up-regulated in the CD38+ cells, it 
seems likely that this contributes to the poor clinical outcome associated 
with CD38 expression. This concept is investigated further in Chapters 5 
and 6 of this thesis.
There is no universal ‘gold standard’ method for the analysis of gene 
expression profiles derived from microarray results so in this study two 
techniques were used and subsequently compared. The first method applied 
filtering techniques (removing absent/marginal genes and removing genes 
that had <2 fold change) and then applied two statistical tests to the genes; 
ANOVA and student’s /-test. The second method applied one filter 
(removing absent/marginal genes) and employed a statistical technique 
designed for microarray analysis called SAM. Out of the 6 genes of interest 
four were present using both methods. ZAP-70 and Akt were present after 
SM2 but not SMI but this does not mean that they are not biologically 
significant. Indeed, there is a body of evident that points to a clear role for 
both ZAP-70 and Akt in determining the clinical course of CLL. (Rassenti 
et al 2004).
In concordance with the gene expression data, VEGF, IL-lp, Akt and 
ZAP-70 were all found to be relatively over-expressed in CD38+ cells
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when compared to their CD38' counter-parts. This indicated that these sub­
populations have activated survival pathways such as the PI3K/Akt 
pathway. Furthermore, this study is in broad agreement with that of 
Huttmann et al ( 2006), who showed that CD38+ CLL cells relatively over 
express genes that are involved in angiogenesis.
CD38+ cells showed consistently higher expression of ZAP-70 irrespective 
of the size of the CD38-expressing population or ZAP-70 positivity 
(whether > 20% of the cells express ZAP-70). Huttmann et al ( 2006) 
found that separation of patients into ZAP-70+/CD38+ and ZAP-707CD38' 
groups could more reliably define good prognosis and poor prognosis 
groups than when either parameter was considered separately. This data 
and the data in this chapter support the conclusions from Chapter 3 of this 
thesis. Namely, that in the clinical setting a composite picture made up of 
CD38 expression, ZAP-70 expression and Vh gene mutation status 
provides more reliable prognostic information.
The relative over-expression of VEGF, IL-lp, CXCL2, CCL3, ZAP-70 and 
Akt may provide a biological rationale to why CD38 expression is 
associated with poor prognosis in CLL. Taken together, the data derived 
from these studies suggests that CD38 might be a rational therapeutic target 
in CLL patients as it seems likely that inhibiting/reducing the expression of 
this molecule may also result in the down-regulation of the genes that are 
relatively over-expressed in CD38+ CLL cells. Ideally this notion would be
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explored using RNA interference methodologies but the challenge of 
transfecting primary CLL cells is not trivial.
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Chapter 5: Vascular endothelial growth factor
In chapter 4 vascular endothelial growth factor (VEGF) was shown to be 
transcriptionally activated in CD38+ CLL cells when compared to CD38‘ 
CLL cells derived from the same patient. VEGF is a glycoprotein made up 
of two 23 kDa subunits and has been shown to play a role in cell migration, 
proliferation, vascular permeability, intracellular Ca2+ influx, and 
chemotaxis (Wang et al. 1999). In the context of CLL, it was recently 
found to be required for chemokine-dependent motility of CLL cells on and 
through endothelium; processes important for the invasion of 
lymphoreticular tissues (Till et al. 2005). Furthermore, McCabe et al 
(2004) showed a correlation between the expression of CD38 and VEGF 
indicating that VEGF may be regulated by CD38 or vice versa. However, 
their study was purely correlative and hence did not directly address this 
question.
Aims: To investigate the protein expression of VEGF to see whether it 
differed between CD38+ and CD38. cells and whether there was a 
difference in the biological role of VEGF between the two sub-populations.
Hypothesis: VEGF will be up-regulated at the protein level in the CD38+ 
cells when compared to their CD38' counterparts and this higher 
expression will help explain why CD38+ cells are associated with poor 
clinical outcome.
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There are three VEGF receptors (VEGFR): VEGFR1 (Flt-1), VEGFR2 
(KDR/Flk) and VEGFR3 (Flt-4). CLL cells have been shown to express all 
three VEGF receptors and all are able to signal (Bairey et al. 2004). 
However, it appears that VEGFR2 is the key VEGFR in CLL as its ligation 
causes a much stronger phosphorylation response in CLL cells (Bairey, 
Boycov, Kaganovsky, Zimra, Shaklai, & Rabizadeh 2004;Lee et al. 2005) 
and its expression has been correlated with cell proliferation and survival 
(Lee, Shanafelt, Bone, Strege, Jelinek, & Kay 2005). In concordance with 
this, VEGFR2 was shown to be highly expressed in a subset of CLL 
patients with aggressive disease; more marked lymphocytosis, severe 
anaemia and shorter survival (Ferrajoli et al. 2001). Interestingly, Bairey et 
al (2004) suggested that this survival effect mediated through VEGFR2 is 
mediated via the PI3K/Akt pathway. It is now clear that CLL cells are 
capable of producing VEGF and possess functional VEGF receptors 
suggesting that both autocrine and paracrine loops might be important in 
the pathogenesis of CLL. Indeed, Farahani et al (2005) showed that VEGF 
signalling can occur through both paracrine (VEGF secreted from another 
cell) and autocrine (endogenous VEGF) signalling pathways in CLL cells, 
and this autocrine signalling produces a protective/survival effect.
Given the link between VEGF and VEGFR2 with poor prognosis in CLL, 
the primary aim of this investigation was to quantify the protein expression 
of VEGF and VEGFR2 in CD38+ and CD38' CLL cells derived from the 
same patient. In addition, the role of both exogenous and endogenous
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VEGF in the in vitro survival of these subsets of CLL lymphocytes was 
examined.
5.1 VEGF expression in CD38+ and CD38' cells from patients with 
bimodal expression of the CD38 antigen
In chapter 4 VEGF transcription was found to be significantly higher in 
CD38+ cells when compared to their CD38‘ counterparts. Since VEGF 
signalling through VEGFR2 is associated with shorter survival (Ferrajoli et 
al 2001), and McCabe et al (2004) found a correlation between VEGF 
expression and CD38 expression, it was decided to investigate whether 
there was a biological link between VEGF and CD38.
The level of VEGF expression was investigated in CD38+ and CD38' cells 
derived from the same patient by flow cytometry (n = 16). The CD38+ and 
CD38' cells were gated and the level of VEGF expression (MFI) was 
investigated in each sub-population (Figure 5.1 A). In addition, CD38+ and 
CD38‘ cells from bimodal patients were physically cell sorted (n = 4) and 
investigated for VEGF expression by Western blotting (4 -  12 % Bis-Tris 
gels and transferred for 1 hour), using the same VEGF antibody that was 
employed in the flow cytometry assay (Figure 5. IB). There was great inter­
patient variability with the level of VEGF expression ranging from 38.5 -  
244.8 MFI units (>6 fold) as measured by flow cytometry. However, 
CD38+ cells were found to have consistently higher expression levels of
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VEGF then their CD38" counterparts (P < 0.0001) and this was confirmed
qualitatively by Western blot analysis.
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Figure 5.1: Differential expression of vascular endothelial growth factor in 
CD38+ and CD38" sub-populations derived from the same patient (n = 16)
(A) VEGF protein expression was found to be significantly higher in CD38* CLL 
cells when compared with CD38' CLL cells derived from the same patient sample 
using flow cytometry. (B) CD38+ and CD38' sub-populations were physically 
sorted by high speed cell sorting and were subsequently Western blotted using the 
same anti-VEGF antibody employed in the flow cytometry assays. CD38 CLL 
cells showed higher expression of VEGF than their paired CD38' counter-parts.
A  number o f  studies have shown the importance o f  VEGFR2 expression in 
predicting aggressive disease and shorter survival in CLL (Ferrajoli et al 
2001). In addition, Farahani et al (2005)show ed that VEGF signalling can 
occur via both paracrine and autocrine pathways. Therefore, this study 
investigated the expression o f  VEGFR2 in CD38^ and CD38' sub­
populations and tried to elucidate whether these distinct sub-populations o f
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CLL cells responded differently to autocrine and paracrine VEGF 
signalling. VEGFR2 expression was quantified in CD38+ and CD38' sub­
populations from CLL patients with bimodal expression of the CD38 
antigen by triple colour flow cytometry in 19 individual patients.
P < 0.0001
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Figure 5.2 VEGFR2 expression in CD38+ and CD38' cells derived from the 
same patient
VEGFR2 expression was investigated in 19 CLL patients with bimodal expression 
of CD38 by triple colour flow cytometry. The expression of VEGFR2 was 
significantly higher in die CD38+ cells when compared to their CD38' 
counterparts. Horizontal bars denote the mean VEGFR2 expression in each CLL 
sub-population.
There was a wide range of VEGFR2 expression between patients ranging 
from almost no VEGFR2 expression (2.3 MFI units) to high expression of 
VEGFR2 (130.7 MFI units). The mean level of expression of VEGFR2 
was 76.3 MFI units for the CD38+ cells and 58.7 MFI units for the CD38' 
cells. VEGFR2 expression was significantly higher in CD38+ cells when 
compared to CD38' cells from bimodal patients (P < 0.0001). Therefore, 
CD38+ CLL cells relatively over expressed both endogenous VEGF and 
VEGFR2. However, it was unclear whether this expression pattern was
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biologically important so a series of experiments were undertaken to 
elucidate this.
5.2: In vitro survival analysis of CD38+ and CD38‘ cells
CD38+ and CD38' cells were physically cell sorted using the MoFlo high 
speed cell sorter (10,000-30,000 cells/second), and then set up in culture to 
analyse whether the over-expression of VEGF was biologically important 
to CD38+ CLL cells. Control cultures were also analysed in which the 
CD38+ and CD38' cell sorting gates were combined to yield a mixed 
‘unsorted’ population that had been subjected to the same cell sorting 
stresses. The levels of apoptosis was analysed in cell sorted samples 
derived from 6 individual CLL patients by flow cytometry using changes in 
forward scatter (giving an index of size of the cells) and side scatter (which 
measures granularity). Typically apoptotic cells are smaller with 
consequently higher granularity than viable cells. Employing this method 
for gating apoptotic cells allowed the simultaneous analysis of VEGF 
expression in the viable cultured CLL cells. Quantification of apoptosis 
was confirmed in parallel experiments using the Annexin V / propidium 
iodide assay. In all the cultures tested, purified CD38+ cells showed the 
lowest percentage apoptosis at each time point. The CD38' cells showed 
the lowest viability and the ‘unsorted’ populations were less viable than the 
CD38+ cells but more viable than the CD38’ cells (Figure 5.3A).
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In addition, the expression of VEGF was measured in the viable cells from 
each of the cell cultures by dual colour flow cytometry (VEGF-FITC / 
CD19-APC). The viable cells were gated using forward scatter and side 
scatter which was then forward gated into each CD19+ dot plot so that only 
the viable CD19+ cells were investigated. VEGF expression (MFI) was 
then quantified using gated histograms. Figure 5.3B shows the VEGF 
expression in the CD38+ CLL cells (183.6 MFI units) the CD38' CLL cells 
(69.2 MFI units) and the ‘unsorted’ population (97.4 MFI units) following 
3 days in culture. At all the time points measured VEGF was consistently 
higher in CD38+ CLL cells when compared to CD38‘ CLL cells (P = 
0.001) or the ‘unsorted’ cultures (P = 0.003).
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Figure 5.3: The association of VEGF with survival in CD38+ and CD38‘ cells
(A) Cells were physically cells sorted using the MoFlo cell sorter and set up in 
culture. The percentage apoptosis was measured per day in each group over an 
eight day period by flow cytometry using forward scatter and side scatter. 
Apoptosis was also measured using the Annexin V / propidium iodide assay. (B) 
VEGF expression (MFI) was investigated by flow cytometry in the viable cells 
from the purified cultures at each time point. Cells were labelled with VEGF- 
FITC and CD19-APC and the viable cells were gated in the forward scatter/ side 
scatter plot. This region was then forward-gated into a CD 19 dot plot. 
Subsequently, the level o f expression of VEGF was analysed in each group. The 
figure shows the relative expression o f VEGF in all three cultures following 3 
days in culture.
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5.3 Mcl-1 expression in bimodal patients of CLL
One effector molecule of VEGF is the anti-apoptotic protein Mcl-1 (Le 
Gouill et al. 2004;Lee et al 2005). Mcl-1 has previously been associated 
with cellular differentiation, proliferation and resistance to apoptosis in 
CLL (Pederson, Kitada, & Leoni 2002;Saxena et al. 2004). Moshynska et 
al (2004) found that CLL patients with high expression of Mcl-1 failed to 
achieve complete remission after drug therapeutics. Consequently, Mcl-1 is 
the subject of a number of on-going studies in our laboratory because of its 
putative role in drug resistance and survival signalling in CLL 
lymphocytes.
Using the programme Pathway Assist (Stratagene), four of the genes that 
were up-regulated in the Microarray experiments (chapter 4); VEGF, IL- 
lp, CCL3 and CXCL2, were found to be directly associated in a pathway 
that controls the expression of the anti-apoptotic protein, Mcl-1 (Figure 
5.4). Based on this pathway data, it was hypothesised that Mcl-1 
expression would be higher in CD38+ CLL cells when compared to their 
CD38' counter-parts.
119
Chapter 5
MCL1 $
Figure 5.4: The control of Mcl-1 by the pathway involving VEGF, IL -ip, 
CCL3 and CXCL2
VEGF, IL-lp, CCL3 and CXCL2 were directly associated in a pathway that 
controls the expression o f the anti-apoptotic protein Mcl-1.
In a separate study in our laboratory, Mcl-1 expression was determined by 
flow  cytometry in 142 CLL patients. The patient cohort was then divided  
into 2 groups; those with Mcl-1 expression above the mean Mcl-1 
expression (>1514 molecules o f  equivalent soluble fluorochrome (MESF)) 
and those patient with Mcl-1 expression below  the mean Mcl-1 expression  
(<1514 MESF). The PFS o f  these two groups was then determined. 
Patients with high Mcl-1 expression had a significantly shorter PFS than 
those patients with low Mcl-1 expression (P = 0.002) indicating that Mcl-1 
expression is prognostic within this CLL patient cohort (Figure 5.5).
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Figure 5.5 Mcl-1 expression in CLL patients (Unpublished data)
Progression-free survival for patients with high expression o f Mcl-1 (>1514 
MESF) and low expression o f Mcl-1 (<1514 MESF). The patients with high 
expression o f Mcl-1 had significantly shorter progression-free survival than those 
patients with Mcl-1 expression below the mean for the entire cohort (P = 0.002).
5.4 Inhibition of VEGF function
McCabe et al (2004) showed that CD38 expression correlates with VEGF 
expression. In addition, CLL cells have been shown to constitutively 
produce VEGF in culture and VEGF signalling provides some 
cytoprotection to CLL cells (Chen et al. 2000). In this study, the effect of 
inhibition of VEGF on cell survival was investigated in CD38+ and CD38' 
sub-populations derived from 3 different patients with bimodal expression 
of the CD38 antigen. Cells were cultured for 24h with or without lpg/ml of 
an anti-VEGF neutralising antibody and/or lOpM of the VEGF signalling 
inhibitor SU1498, which is a potent and selective inhibitor of vascular 
endothelial growth factor receptor 2 kinase activity (Strawn et al. 1996). As 
VEGF has been shown to signal via both paracrine and autocrine signalling 
mechanisms (Farahani et al. 2005), both the anti-VEGF neutralising 
antibody and the VEGF inhibitor SU1498 were employed to establish
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whether autocrine or paracrine signalling was the predominant effector in 
the CD38+ and CD38' sub- populations.
Treatment with the VEGF antibody had little effect on CD38+ or CD38" 
cells, whereas treatment with SU1498 caused a significant increase in 
apoptosis in both CD38+ and CD38' cells (Figure 5.6A). This suggests that 
both sub-populations predominantly rely on signals generated by 
endogenous VEGF as SU1498 had a larger effect on survival. However, 
the combination of inhibitors produced the largest increase in apoptosis in 
both the CD38+ and the CD38' cells suggesting that both sub-populations 
utilise endogenous and exogenous VEGF.
5.5 Cytoprotection effect of recombinant VEGF in CD38+ and CD38' 
sub-clones
The data presented here suggest that VEGF expression plays a role in 
maintaining CLL cell survival in vitro. To investigate this further 
recombinant VEGF was added to cultures of CD38+ and CD38' cells to see 
whether there was any effect on spontaneous apoptosis. CD38+ and CD38' 
CLL cells derived from 4 different patients were cultured for 24h with or 
without lOOng/ml recombinant VEGF. This concentration of VEGF has 
previously been shown to induce cytoprotection in unsorted CLL cells by 
Farahani et al (2005). Both sub-populations showed a decrease in 
spontaneous apoptosis after 24h following the addition of recombinant 
VEGF. However, this was only statistically significant in the CD38' sub­
122
Chapter 5
populations (P = 0.02) (Figure 5.6B). In order to try to rationalise this 
result, Mcl-1 expression was measured by flow cytometry in the CD38+ 
and CD38' cells derived from the same patient cultured with and without 
the addition of recombinant VEGF for 24h. In keeping with the previous 
findings, Mcl-1 expression was consistently higher in the CD38+ CLL cells 
(Chapter 7, Figure 7.3C). However, the addition of recombinant VEGF 
resulted in a marked increase in Mcl-1 expression in the CD38‘ cells and a 
more modest increase in the CD38+ cells (Figure 5.6C).
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Figure 5.6: Effect of VEGF on in vitro CLL cell survival.
(A) CD38" and CD38' sub-populations derived from bimodal patients were 
cultured for 24h with or without 1 |ig/ml o f an anti-VEGF neutralising antibody 
and/or lOpM o f the VEGF receptor inhibitor SU1498. Treatment with the 
neutralising antibody had no significant effect on survival in either the CD38+ or 
CD38' sub-populations whereas the VEGF receptor inhibitor SU1498 caused a 
significant decrease in cell viability in both sub-populations. (B) CD38+ and 
CD38' sub-clones derived from 4 different patients were cultured for 24h with or 
without lOOng/ml recombinant VEGF. Both the CD38+ and CD38* CLL cells 
showed a decrease in apoptosis in the VEGF-treated cultures but this only reached 
significance in the CD38" sub-populations (P = 0.02). (C) Mcl-1 expression was 
measured by flow cytometry in the sub-populations cultured with and without the 
addition o f recombinant VEGF for 24h. Both the CD38+ and CD38' sub­
populations showed an increase in Mcl-1 expression following exposure to VEGF 
and this was most marked in the CD38‘ CLL cells (P = 0.01).
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5.6 Conclusion
In chapter 4 VEGF was found to be relatively transcriptionally activated in 
CD38+ cells when compared to their CD38' counter-parts derived from the 
same patient. VEGF was also found to be expressed significantly higher in 
the CD38+ cells when compared to the CD38’ cells from the same patient at 
the protein level. McCabe et al (2004) found a direct correlation between 
CD38 expression and VEGF expression. This, along with our data, 
suggests that VEGF may be regulated by CD38 or CD38 may regulate 
VEGF. To prove this conclusively a series of experiments would be 
required involving knock-down experiments where VEGF would be 
knocked down with antisense RNA or SiRNA. Also knock-in experiments 
where CD38 would up-regulated by using gene transfer. These two 
techniques are a challenge in CLL cells.
VEGFR2 expression has been shown to be important in CLL in predicting 
disease and shorter survival (Ferrajoli et al 2001). Farahani et al (2005) 
also showed that VEGF can signal via autocrine and paracrine pathway. In 
this study, VEGFR2 was found to be relatively over expressed at the 
protein level in the CD38+ cells, but it was also found to be expressed to a 
lesser degree in the CD38’ cells. This suggested that both sub-populations 
were capable of signalling via exogenous VEGF as evidenced by the 
experiments using recombinant VEGF in cell sorted populations of CLL 
cells.
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Even though VEGF was shown to be relatively over expressed (both 
transcriptionally and at the protein level) in the CD38+ cells when 
compared to their CD38' counter-parts, this did not indicate whether this 
over expression was biologically important to the CD38+ CLL cells. An 
investigation into spontaneous apoptosis showed that CD38+ cells had the 
lowest spontaneous apoptosis and CD38‘ cells had the highest levels of 
spontaneous apoptosis. Concomitantly, VEGF expression was found to be 
higher in the CD38+ sub-populations, and lower in the CD38' sub­
populations, indicating a correlation between VEGF expression and 
survival. This cytoprotection of the CD38+ cells by VEGF was abrogated 
by the use of the inhibitor SU1498, but the anti-VEGF blocking antibody 
had no significant effect on the survival of either sub-populations. Addition 
of the recombinant VEGF caused a reduction in spontaneous apoptosis in 
the CD38* cells despite the fact that these sub-populations expressed less 
VEGFR2 than their CD38+ counter-parts. This indicates that CD38+ CLL 
cells preferentially utilise an internal autocrine survival loop whereas 
CD38' sub-clones are possibly more dependent on exogenous VEGF to 
maintain optimal cell viability as they do not produce enough endogenous 
VEGF. In bimodal patients, it is feasible that CD38+ cells can provide 
exogenous VEGF for the CD38' cells. This notion is supported by the 
apoptosis experiments in which the unsorted population showed less 
spontaneous apoptosis than the purified CD38' CLL cells.
Four genes found to be highly expressed in the CD38+ cells in the 
microarray experiments, VEGF, IL-lj$, CXCL2 and CCL3, were found to
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be directly associated with the control of the expression of Mcl-1. 
Importantly, the anti-apoptotic protein Mcl-1 has previously been shown to 
be a down-stream effector of VEGF signalling (Le Gouill et al 2004). 
Furthurmore, Mcl-1 has been shown to be associated with poor response to 
chemotherapy (Moshynska et al. 2004) and in an independent study within 
our laboratory Mcl-1 was shown to be prognostically relevant as patients 
with high Mcl-1 expression had shorter PFS than patients with low Mcl-1 
expression. This suggests that the Mcl-1 expression may contribute to the 
enhanced cytoprotective phenotype exhibited by the CD38+ cells, and this 
may be influenced by the high VEGF expression.
When recombinant VEGF was added to the CD38' cells, there was a 
marked elevation in their Mcl-1 expression but even this failed to achieve 
comparable expression to their CD38+ counter-parts. This indicates that the 
autocrine VEGF signalling utilised the CD38+ sub-populations may be a 
more effective inducer of Mcl-1 expression than exogenous VEGF. 
Alternatively, CD38+ CLL cells may be subject to other Mcl-1-inducing 
pathways such as those triggered by BCR ligation. In this regard, some 
groups have shown that BCR ligation can induce Mcl-1 expression (Pepper 
et al. 2006;Petlickovski et al. 2005).
It has been shown that CD38 expression is higher in CLL cells in the bone 
marrow and lymphoid tissues compared to the peripheral blood (Ghia et al. 
2003). This indicates that once the cells leave the bone marrow, the 
expression of CD38 may decrease and so the higher the CD38 expression
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in the peripheral blood, the higher the turnover/renewal from the bone 
marrow and lymph nodes.
This data provides a biological rationale for the poor prognosis associated 
with CD38 expression in CLL. It also provides evidence that both Mcl-1 
and VEGF may prove to be useful therapeutic targets in the treatment of 
patients with poor prognosis CLL. The control of VEGF and Mcl-1 is 
likely to be complex and will require further investigation.
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Chapter 6: The role of the PI3K pathway.
In Chapter 4 CD38+ sub-populations were shown to possess a different 
transcriptional signature when compared to their CD38' counter-parts 
derived from the same patient. Chapter 5 was in part a validation of these 
findings by confirming that the increased transcription of one of these 
genes, VEGF, resulted in elevated VEGF protein expression in CD38+ 
CLL cells. Further validation of the microarray results is continued in this 
chapter by investigating the protein expression of Akt. Akt is a member of 
the phosphoinositol-3 kinase (PI3K) pathway, was found to be 
differentially expressed between CD38+ and CD38' cells derived from the 
same patient. Interestingly, Bairey et al (2004) suggested that VEGF 
survival signalling occurs via the PI3K pathway indicating that the 
activation of Akt and VEGF may be biologically linked.
Aims: To determine whether the PI3K pathway is differentially regulated 
in CD38+ CLL cells compared to CD38' CLL cells.
Hypothesis: The PI3K pathway is up-regulated in CD38+ cells when 
compared to their CD38' counterparts, which gives the CD38+ cells a 
survival advantage.
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6.1 Validation of Microarray
Akt, a member o f  the PI3K pathway has previously been shown to be 
constitutively active within CLL cells (Cuni et al. 2004). In Chapter 4 
transcription o f  Akt was found to be significantly higher in the C D 38f cells  
when compared to their CD38' counter-parts by microarray analysis. To 
confirm this at the protein level Akt was measured by triple colour flow  
cytometry (Akt-FITC, CD38-PE and CD 19-APC) in C D 38+ and CD38' 
cells from 31 patients with bimodal expression o f  CD38.
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Figure 6.1 Expression of Akt in CD38+ and CD38' sub-populations derived 
from the same patient.
Akt expression was determined in CD38 and CD38' sub-populations derived 
from 31 patients with bimodal expression o f the CD38 antigen by triple colour 
flow cytometry (Akt-FITC, CD38-PE and CD 19-APC) on fixed and 
permeabilised cells. The data was analysed using a paired Student’s /-test and Akt 
was found to be expressed at significantly higher levels in CD38’ sub-populations 
when compared to their CD38' counter-parts (P < 0.0001).
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Most patients demonstrated higher Akt expression in their CD38+ CLL 
cells when compared to their paired CD38' CLL cells. However, 1/31 
samples showed higher Akt expression in the CD38' sub-populations when 
compared to the CD38+ CLL cells suggesting that there may be other 
mechanisms that impact upon Akt expression in CLL cells that are not 
associated with CD38 expression. The level of expression of Akt varied 
greatly between patients ranging from 61.3 -  276.2 MFI units. Using a 
paired Student /-test Akt protein expression was found to be significantly 
higher in the CD38+ sub-populations when compared to their CD38' 
counter-parts (P < 0.0001) (Figure 6.1).
6.2 Post-translational Modifications
Activation of Akt occurs by phosphorylation on two residues, Threonine 
308 (Thr 308) by the molecule Phosphoinositol dependent kinase-1 
(PDK1), and Serine 473 (Ser 473) by an unknown protein termed 
Phosphoinositol dependent kinase-2 (PDK2) (Feng et al. 2004). Akt is 
initially phosphorylated on Thr308 in the activation loop of the kinase 
domain by PDK1 and then phosphorylated on Ser473 in the C-terminal 
hydrophobic motif by an unknown molecule that has been termed PDK2 
(Bayascas & Alessi 2005;Feng et al 2004). There have been suggestions 
that CD38 expression is associated with a more activated phenotype 
(Morabito et al. 2006;Pittner et al. 2005) and so an investigation was 
undertaken to determine whether CD38+ cells had higher expression of p- 
Akt (Ser 473) and p-Akt (Thr 308) than their CD38' counter-parts.
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CD38+ and CD38‘ cells were investigated from CLL patients with bimodal 
expression of CD38 by triple colour flow cytometry (p-Akt (Ser 473 or Thr 
308)-FITC, CD38-PE and CD 19-APC).
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Figure 6.2 Protein expression of (A) p-Akt (Ser 473) and (B) p-Akt (Thr 308) 
in CD38+ and CD38' cells from the same patient.
Expression o f p-Akt (Ser 473) and p-Akt (Thr 308) was determined in CD38+ and 
CD38' CLL cells derived from patients with bimodal expression o f the CD38 
antigen by triple colour flow cytometry (p-Akt-FITC, CD38-PE and CD 19-APC). 
The data was analysed using a paired Student’s r-test and both p-Akt (Ser 473) 
and p-Akt (Thr 308) was found to be expressed significantly higher in CD38+ sub­
populations when compared to their CD38' counter-parts (P < 0.0001 and P = 
0.0066 respectively).
For both phosphorylation states o f  Akt (p-Akt (Ser 473) and p-Akt (Thr 
308) there was great inter-patient variability but the majority o f  patients 
showed higher phosphorylation levels o f  both residues in their C D 38+ cells.
133
Chapter 6
As was found in the total Akt analyses, the level of expression 
phosphorylated Akt varied greatly between patients ranging from 22.7 -
88.5 MFI units (p-Akt Ser 473) and 60.4 -  314.4 MFI units (p-Akt Thr 
308). A statistical evaluation of the expression of p-Akt (Ser 473) and p- 
Akt (Thr 308) revealed that they were expressed at significantly higher 
levels in the CD38+ cells when compared to their CD38' counter-parts 
(paired Student’s /-test ; P < 0.0001 and P = 0066 respectively). 
Furthermore, the levels of p-Akt and total Akt correlated for each patient 
tested (P = 0.017 ?  = 0.1445)
6.3 PDK1 and S6 Ribosomal Protein
PDK1 is responsible for phosphorylating Akt at the Thr 308 residue (Mora 
et al. 2004). Given that p-Akt (Thr 308) was differentially expressed 
between CD38+ and CD38‘ cells from the same patient, PDK1 was 
measured by Western blotting and flow cytometry to determine whether it 
was differentially expressed in CD38+ and CD38' CLL cells. In addition, 
an important downstream effector molecule of the PI3K pathway, S6 
ribosomal protein (Petroulakis et al. 2006), was also investigated to see 
whether it was expressed (and phosphorylated) differentially in CD38+ and 
CD38' cells from the same patient. Cells from 28 patients with bimodal 
expression of CD38 were investigated for p-S6, S6 and PDK1 expression 
by triple colour flow cytometry. The data were then analysed using the 
paired Student’s /-test.
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Figure 6.3: Protein expression of (A) PDK1, (B) p-S6 and (C) total S6 in 
CD38+ and CD38' cells from the same patient.
CD38 and CD38‘ sub-populations were analysed using triple colour flow 
cytometry (PDK1 or p-S6 or S6 -  FITC, CD38-PE and CD19-APC). The data was 
analysed using a paired student’s Mest. The expression o f PDK1 and total S6 was 
found to be significantly higher in the CD38" CLL cells when compared to their 
CD38' counter-parts. However, there was no significant difference in p-S6 
expression between the two sub-populations.
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The expression o f  PDK1, p-S6 and total S6 varied between patients 
ranging from 17.5 -  67.9 MFI units (PDK1), 40.0 -  422.1 MFI units (p-S6) 
and 7.8 -  28.1 MFI units (total S6). There was also variation in these 
proteins in the CD38' or CD38' CLL cells. U sing a paired Student’s /-test 
PDK1 and total S6 were shown to be expressed at significantly higher 
levels in C D 3 8 1 cells when compared to their CD38' counter-parts derived  
from the same patient (P < 0.0001 and P = 0 .0002 respectively). H owever 
there was no significant difference in expression levels o f  p-S6 (P = 0.98).
The level o f  expression o f  PDK1, p-S6 and total S6 w as also investigated  
by Western blotting in C D 384 and CD38 patients (using the sam e patient 
cohort analysed by flow  cytometry). The samples were run on 4-12%  B is- 
Tris gels and then blotted (transferred) for 1 hour. The same antibodies 
em ployed for the flow  cytometry assay were used, with P-actin as a loading  
control.
PDK1 
p-S6
P-actin
Figure 6.4: Western blot analysis of PDK1 and p-S6 expression in different 
CLL patients
6 CLL patients were analysed for PDK1 and p-S6 expression using Western blot 
analysis. The samples were run on 4 -  12% Bis-Tris gels and then transferred for 
1 hour. The same antibodies employed for the flow cytometry assay were used, 
with P-actin (45kDa), as a loading control. The differential expression o f PDK1 
and p-S6 did not appear to be associated with VH gene mutation status or CD38 
expression.
C L L #  1
136
Chapter 6
Patients #1 -  #5 had unmutated V h genes and patients #1 -  #3 were CD38' 
whereas patients #4 and #5 were C D 38'. Patient #6 was also CD38* but 
had mutated V h genes. Both PDK1 (58 -  68 kDa) and p-S6 (32kDa) were 
differentially expressed between CLL patients. However, the expression  
profile o f  PDK1 and p-S6 did not appear to be associated with either V h 
gene mutation status or CD38 expression when com paring the different 
CLL patient samples. This was also true when looking at the expression o f  
PDK1 and p-S6 by flow  cytometry. Neither PDK1 nor p-S6 were 
associated with V H gene mutation status (P = 0 .94  and 0.56 respectively) or 
CD38 expression (P = 0.34 and P = 0.87 respectively).
CLL patient #1 #2 #3 #4  #5
P - a c t i n
T o t a l  S 6
Figure 6.5: Western blot analysis of S6 expression in different CLL patients
5 CLL patients were analysed for total S6 expression using Western blot analysis. 
The samples were run on 4 -  12% Bis-Tris gels and then transferred for 1 hour. 
The same antibodies employed for the flow cytometry assay were used, with (3- 
actin (45kDa), as a loading control. The expression o f total S6 did not appear to 
be differentially expressed between patients.
Patients #1 -  #3 had unmutated V h genes and patients #4  and #5 had 
mutated V h genes. Patients #1 and #4  were C D 38' and patients #2, #3 and 
#5 were CD38". There did not appear to be any significant difference in S6 
expression (32kDa) between any o f  the CLL patient sam ples tested. 
Importantly, the rank order o f  normalised S6 expression in the patient
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samples as determined by Western blotting was the same as the rank order 
of expression of S6 in these samples as measured by flow cytometry.
Previously it has been shown that PDK1 phosphorylates Akt on Thr 308 
(Feng, Park, Cron, Hess, & Hemmings 2004) and there have been 
suggestions that PDK1 can also phosphorylate Akt on Ser 473 (Balendran 
et al. 1999). Therefore an investigation of the relative expression of these 
proteins in CLL samples was carried out. Since p-S6 is at the distal end of 
the PI3K pathway (Petroulakis et al 2006) and is an essential effector 
molecule, an investigation into whether PDK1 and S6 correlated was also 
carried out. PDK1, Akt, p-S6 and S6 expression levels (MFI) were 
determined by triple colour flow cytometry in 61 CLL patients and the data 
were analysed using GraphPad Prism 3.0.
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Figure 6.6 Correlation between (A) Akt and PDK1, (B) p-S6 and PDK1 and 
(C) Total S6 and PDK1
The level o f  expression o f the proteins Akt, PDK1, p-S6 and total S6 was 
determined by dual colour flow cytometry (Akt, PDK1, p-S6 and S6-FITC and 
CD 19-APC). Correlation analysis was carried out in GraphPad Prism 3.0 
software. Akt, p-S6 and S6 all correlated with PDK1 expression. Total Akt 
expression was analysed due to lack o f confidence in the p-Akt antibodies.
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As expected, PDK1 expression was positively correlated with Akt 
expression in CLL cells (P = 0.03, r2 = 0.1). The r2 value of 0.1 indicated 
that approximately 10% of the variation in Akt expression was attributable 
to changes in PDK1 expression. Hence 90% of the variation in Akt 
expression was associated with factors other than PDK1 expression. PDK1 
expression was also positively correlated with p-S6 (P = 0.01, r2 = 0.1) and 
total S6 (P < 0.0001, r2 = 0.37). Interestingly, total S6 levels correlated 
more closely with PDK1 than p-S6 levels suggesting that PDK1 may be 
involved in the transcriptional regulation of S6 rather than the post- 
translational modification of S6 in CLL cells.
6.4 PTEN
PTEN is a known negative regulator of the PI3K pathway. It de- 
phosphorylates phosphatidylinositol-3,4,5-trisphospate (PIP3) into 
phosphatidylinositol-3,4-bisphosphate (PIP2), effectively switching the 
PI3K pathway off (Waite & Eng 2002). The protein expression level of 
PTEN and p-S6 was investigated in CLL patients by Western blotting. The 
samples were run on 4 — 12% Bis-Tris gels (with P-actin as a loading 
control) and blotted (transferred) for one hour.
140
Chapter 6
CLL# 1
PTEN
p-S6
P-actin
Figure 6.7 Western blot analysis for PTEN and p-S6 expression
6 CLL patients were analysed for PTEN and p-S6 expression using Western blot 
analysis. The samples were run on 4 -  12% Bis-Tris gels and then transferred for 
1 hour. The same antibodies employed for the flow cytometry assay were used, 
with P-actin (45kDa), as a loading control. The expression o f PTEN did not 
appear to be differentially expressed between patients, whereas p-S6 expression 
was differentially expressed between these patients.
Patients #2, #3 and #4 were CD38+ (>30% CD38 expression) whereas 
Patients #1, #5 and #6 were CD38' (<30% CD38 expression). Also patients 
#1, #3, #4 and #6 had mutated Vh genes whereas patient #2 had unmutated 
V h genes. There appeared to be no significant difference in expression of 
PTEN (54kDa) between the CLL patients analysed. However the same 
patients showed differential expression of p-S6 (32kDa) but again there did 
not seem to be an association between p-S6 expression and VH gene 
mutational status or CD38 expression.
6.5 Conclusion
In the microarray analysis in Chapter 4, Akt transcription was shown to be 
relatively increased in CD38+ CLL cells when compared to CD38‘ CLL 
cells derived from the same patient. In this investigation, this was also 
found to be true at the protein level. Akt is activated by phosphorylation on
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two residues, serine 473 and threonine 308. Both phosphorylation sites of 
Akt were were more frequently phosphorylated in CD38+ sub-populations 
when compared to their CD38' counter-parts. This indicates that CD38+ 
cells have higher levels of activated Akt, and therefore have a more 
activated phenotype which is in agreement with the findings of Cuni et al 
(2004). Since these CLL cells appear to be more activated, this provides a 
rationale for the poor prognosis of CLL patients that express the CD38 
antigen.
PDK1 is the molecule that phosphorylates Akt on Thr 308 residue (Feng et 
al 2004;Mora et al 2004) and was also found to be expressed significantly 
higher in cells that express CD38 compared to those that do not. Total S6, 
which is a molecule at the distall end of the PI3K pathway (Petroulakis et 
al 2006) was also more highly expressed in CD38+ cells compared to their 
CD38' counter-parts. Intriguingly, the phosphorylated form of S6 was not 
found to be significantly different between CD38+ and CD38‘ cells from 
the same patient. This suggests that the PI3K pathway signalling via S6 is 
probably not biologically important in distinguishing between CD38+ and 
CD38' cells.
When comparing CD38+ CLL patients (>30% CD38 expression) to CD38' 
CLL patients (<30% CD38 expression), the expression levels of p-S6, S6 
and PDK1 were not significantly different. An explanation for this may be 
that the lower protein expression found in CD38' sub-populations in 
bimodal patients causes a reduction in the mean protein expression for the
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whole sample resulting in no statistically significant difference between 
these PI3K proteins in CD38+ and CD38' patient samples.
There was a positive correlation between Akt expression and PDK1 
expression which was expected as PDK1 phosphorylates Akt on Thr 308 
residue (Cuni et al 2004). It has also been suggested that PDK1 attached to 
PIF (PDK1 interacting fragment) may be the elusive PDK2 which 
phosphorylates Akt on Ser 473 residue (Balendran et al 1999). PDK1 
expression was also positively correlated with p-S6 expression and total S6 
expression when comparing CD38+ and CD38' cells from the same 
patients. This was also expected as PDK1 can phosphorylate p70 S6 kinase 
(S6K) directly (and indirectly through Akt) which then phosphorylates S6 
(Balendran, Currie, Armstrong, Avruch, & Alessi 1999). In addition, 
PTEN, a known negative regulator of the PI3K pathway (Waite & Eng 
2002) was not differentially expressed within the CLL patient cohort. This 
suggests that PTEN is not likely to play a major role in the control of the 
PI3K pathway in CLL cells or in determining the clinical course of the 
disease.
Taken together, these data suggests that although the PI3K pathway/Akt is 
important in CLL cells (Cuni et al 2004), signalling via S6 (i.e. activation 
of the distall end of the canonical PI3K pathway) does not appear to 
significantly contribute to the altered biology of CD38-expressing CLL 
cells. However, the relative over-expression of Akt in the CD38+ CLL cells 
does suggest that the PI3K pathway may result in the activation of other
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molecular targets not considered in this study (e.g. NF-kB) that possibly 
contribute to the association of CD38 expression with poor prognosis. This 
notion is currently under investigation in our laboratory.
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Chapter 7: Drug Sensitivity of CD38+ and CD38' cells
CLL is a disease where lymphocyte accumulation is caused, at least in part, 
by failed apoptosis (Pepper et al. 1999). This failure of the apoptotic 
machinery is thought to be due to dysregulation of apoptotic proteins such 
as the Bcl-2 family proteins, for example, Bcl-2 (B cell lymphoma protein 
2), Bax (Bcl-2 associated X protein) and Mcl-1 (Myeloid cell leukaemia 
sequence 1) (Pepper et al 1999;Saxena et al. 2004). Many studies have 
shown that high expression of Bcl-2 and Mcl-1 in CLL patients is 
associated with poor response to therapeutic drugs (Kitada et al. 
1998;Pepper et al. 2001). In addition, the ratio of pro- and anti-apoptotic 
proteins has been shown to be important in disease progression and 
response to chemotherapy (Kitada et al 1998;Saxena et al 2004).
Aims: To investigate whether CD38+ sub-clones were more resistant to 
drug chemotherapy than their CD38' counter-parts, and whether the 
apoptotic proteins Bcl-2, Bax and Mcl-1 were differentially expressed 
within these two sub-clonal populations.
Hypothesis: CD38+ cells are more resistant to drug chemotherapy due to 
high expression of the anti-apoptotic proteins Bcl-2 and Mcl-1 when 
compared to CD38' cells.
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7.1 The sensitivity of CD38+ and CD38' cells from the same patient to 
fludarabine.
CD38+ and CD38‘ cells were physically cell sorted from 25 patients with 
bimodal expression of CD38 using the MoFlo high speed cell sorter and set 
up in culture. Different concentrations of fludarabine were added to the 
cultures for 48 hours and the amount of apoptosis was measured by flow 
cytometry using forward scatter and side scatter plots. Forward scatter 
measures the size of the cells and side scatter measure the granularity of the 
cells. This helps to distinguish apoptotic cells from viable cells as cells 
undergoing apoptosis become smaller and more granular. The data from 
these experiments were confirmed by using the Annexin W Propidium 
iodide assay. Dose-response curves were produced by plotting the amount 
of apoptosis produced by each concentration of fludarabine and the LD50 
values (the concentration at which 50% of the cells were killed) were 
determined for both the CD38+ and CD38' sub-clonal populations. For 20 
of the 25 patient samples analysed the L D 5 0  for both the CD38+ and CD38' 
sub-clones were not statistically significantly different (P = 0.44) indicating 
that both CD38+ and CD38' cells had similar sensitivity to fludarabine. 
Figure 7.1 A shows an example of the comparative sensitivity of CD38+ 
and CD38’ cells derived from a single CLL patient. Figure 7.IB shows the 
relative sensitivity to fludarabine of CD38+ and CD38" cells derived from 
20 CLL patients.
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Figure 7.1 Comparative in vitro sensitivity to fludarabine in CD38+ and 
CD38 CLL cells.
CD38+ and CD38' cells were high speed cell sorted and set up in culture where 
they were incubated with or without fludarabine for 48 hours. The amount of 
apoptosis was determined by flow cytometry using forward scatter and side 
scatter plots. The concentration of fludarabine that killed 50% of the CLL cells 
(LD50) was similar for both CD38+ and CD38' cells. (A) shows the overlaid dose- 
response curves for CD38+ and CD38' CLL cells derived from a single patient. 
(B) shows the comparative fludarabine sensitivity of CD38+ and CD38' cells 
derived from 20 CLL patients.
In contrast, five patients who had previously received at least four different 
treatment regimens displayed differential sensitivity to fludarabine with the 
CD38' cells having a similar LD50 to those patients who had not previously 
received treatment whereas the CD38+ cells were markedly more resistant 
to fludarabine. Figure 7.2A shows the overlaid dose-response curves for
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CD38+ and CD38' cells derived from a single CLL patient. Figure 7.2B 
shows the comparative sensitivity of CD38+ and CD38' cells derived from 
the five heavily treated patients. It should be noted that the sensitivity of 
the CD38' cells derived from these five patients was similar to that seen in 
the other 20 patients in the cohort. Only the CD38+ CLL cells showed a 
marked increase in drug resistance to fludarabine.
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Figure 7.2 Comparative in vitro sensitivity to fludarabine in CD38+ and 
CD38‘ CLL cells derived from heavily treated CLL patients, Apoptosis was 
determined in cell sorted CD38+ and CD38' cells derived from the same patient by 
flow cytometry using forward scatter and side scatter plots. CD38+ cells were 
more resistant to fludarabine than their CD38' counter-parts shown by their LD50 
values. (A) shows the overlaid dose-response curves for CD38+ and CD38" CLL 
cells derived from a single patient. (B) shows the comparative fludarabine 
sensitivity of CD38+ and CD38' cells derived from five heavily treated CLL 
patients.
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7.2 Expression of the apoptotic proteins Bcl-2, Bax and Mcl-1 in CD38+ 
and CD38~ cells.
Dysregulation of apoptotic proteins has been suggested as an explanation 
for why CLL lymphocytes fail to undergo apoptosis (Pepper, Thomas, 
Hoy, Cotter, & Bentley 1999;Saxena, Viswanathan, Moshynska, Tandon, 
Sankaran, & Sheridan 2004). Bcl-2 has been shown to be differentially 
expressed in CLL and plays an important role within the disease (Pepper, 
Thomas, Hoy, Cotter, & Bentley 1999). Bcl-2/Bax ratios have also been 
shown to be prognostic (Oltvai, Milliman, & Korsmeyer 1993;Pepper, 
Thomas, Hoy, Cotter, & Bentley 1999) along with Me-1/Bax ratios 
(Bellosillo et al. 2002). Mutations in the pro-apoptotic bax gene also appear 
to influence how patients respond to drug therapies (Starczynski et al. 
2005).
Recently Mcl-1 has been put forward as an important prognostic factor 
within CLL lymphocytes (Kitada, Andersen, Akar, Zapata, Takayama, 
Krajewski, Wang, Zhang, Bullrich, Croce, Rai, Hines, & Reed 
1998;Saxena, Viswanathan, Moshynska, Tandon, Sankaran, & Sheridan 
2004). Faderl et al ( 2002) looked at many prognostic proteins and found 
that Bcl-2 predicted the patients with the worst clinical outcome. We have 
shown greater prognostic significance than Bcl-2 or any other apoptotic 
protein (Unpublished data). Mcl-1 was shown to be differentially expressed 
between CLL patients and in Chapter 5 Mcl-1 was shown to be prognostic
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as patients with high Mcl-1 expression had a shorter PFS than patients with 
low Mcl-1 expression.
In this study, the expression level of Bcl-2, Bax and Mcl-1 was measured 
in 45 patients with bimodal expression of CD38 by triple colour flow 
cytometry (protein of choice-FITC, CD38-PE and CD 19-APC). The level 
of expression of each protein was investigated in the CD38+ and CD38' 
sub-populations from the same patient with bimodal expression of CD38 
using a paired student’s Mest.
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Figure 7.3 (A) Bcl-2, (B) Bax and (C) Mcl-1 expression in paired CD38+ and 
CD38~ sub-populations derived from the same patient
CD38+ and CD38" cells from 45 patients with bimodal expression o f CD38 were 
analysed by triple colour flow cytometry on fixed and permeabilised cells for 
expression levels o f the apoptosis-regulating proteins Bcl-2, Bax and Mcl-1. The 
data were analysed using a paired t test. In all three cases the protein expression 
levels were found to be statistically higher in the CD38+ sub-populations when 
compared to the CD38' sub-populations.
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Most of the CLL patients had higher protein expression in their CD38+ 
cells when compared to their CD38' cells. However, 9 out of 45 patients 
had higher Bcl-2 expression in their CD38' cells, 5 out of 45 patients had 
higher Bax expression in their CD38' cells and 6 out of 45 patients had 
higher Mcl-1 expression in their CD38‘ cells when compared to the CD38+ 
cells. There was also great inter-patient variability with Bcl-2 expression 
ranging from 37.1 -  341.9 MFI units, Bax expression ranging from 6.0 -  
103.6 MFI units and Mcl-1 expression ranging from 11.9 -  202.3 MFI 
units. Using a paired /-test all three proteins were expressed at significantly 
higher levels in CD38+ sub-populations when compared to their CD38' 
counter-parts. The highest significance difference between CD38+ and 
CD38' cells was found in Mcl-1 expression (P < 0.0001) compared to Bcl- 
2 expression (P = 0.0009) and Bax expression (P = 0.0006).
High Bcl-2/Bax and Mcl-1/Bax ratios have been associated with poor 
response to chemotherapy (Bannerji et al. 2003;Pepper, Thomas, Hoy, 
Cotter, & Bentley 1999). An investigation into the Bcl-2/Bax ratios and 
Mcl-1/Bax ratios in CD38+ and CD38' sub-populations derived from the 
same patient showed that neither the Bcl-2/Bax ratios nor the Mcl-1/Bax 
ratios were significantly different between the two sub-populations (P = 
0.22 and P = 0.26 respectively) (Figure 7.4).
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Figure 7.4 (A) Bcl-2/Bax ratios and (B) Mcl-l/Bax ratios in CD38+ and CD38' 
sub-populations derived from the same patient.
Bcl-2, Bax and Mcl-1 expression was determined by triple colour flow cytometry 
in 44 patients with bimodal expression of the CD38 antigen. The Bcl-2/Bax ratios 
and Mcl-l/Bax ratios were compared in the CD38+ and CD38' sub-populations 
derived from the same patient and analysed using a Student’s t test. Neither the 
Bcl-2/Bax ratios nor Mcl-l/Bax ratios were significantly different when 
comparing the CD38+ and CD38‘ populations.
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7.3 Conclusion
Lymphocyte accumulation in CLL is due in part to dysregulation of the 
apoptotic proteins which leads to failed apoptosis (Pepper et al 1999). This 
dysregulation of the apoptotic proteins, such as Bcl-2, Bax and Mcl-1 has 
shown to be associated with poor responsiveness to chemotherapy (Kitada 
et al 1998). CD38 expression has also been associated with poor response 
to chemotherapy (Deaglio et al. 2006).
As investigation into the response of CD38+ and CD38' sub-populations 
(derived from the same patient) to the therapeutic drug fludarabine 
revealed that in most cases (20/25) the LD50 for both CD38+ and CD38' 
sub-clones were similar, indicating that neither sub-population was more 
resistant to fludarabine. However, in a subset of 5 patients, who had 
previously received at least four separate treatment regimens, the CD38+ 
sub-clones showed a marked increase in resistance to fludarabine whereas 
the CD38‘ sub-clones retained the same sensitivity as that found in samples 
derived from untreated patients. These 5 patients had not been treated in a 
uniform fashion but had been subjected to a number of different drug 
treatments and so the preferential resistance found in the CD38+ sub­
populations did not appear to be mediated by exposure to a specific agent.
The apoptotic proteins Bcl-2, Bax and Mcl-1 were all expressed at 
significantly higher levels in the CD38+ sub-populations when compared to 
their CD38‘ counter-parts. The high expression of Bcl-2 and Mcl-1 in the 
CD38+ sub-clones was as expected since both Bcl-2 and Mcl-1 expression
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has been associated with poor clinical response (Kitada et al 1998;Pepper 
et al 1999) and this may be an explanation to why CD38 expression is 
associated with poor prognosis. However, the high expression of Bax was 
unexpected, as Bax is a pro-apoptotic protein (Banneiji et al 2003). The 
elevated Bax expression contributed to the lack of significant difference in 
the Bcl-2/Bax and Mcl-1/Bax ratios between CD38+ and CD38' CLL cells 
and this may provide an explanation for why most of the paired CD38+ and 
CD38' sub-clones showed similar sensitivity to in vitro fludarabine.
Further experiments need to be carried out in which the levels of Bcl-2, 
Bax and Mcl-1 expression are measured in the CD38+ and CD38' sub­
clones pre- and post treatment in a longitudinal fashion. These experiments 
will address the issue of preferential clonal evolution resulting in elevated 
drug resistance in the CD38f sub-clones.
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Chapter 8: Discussion
CD38 is a 45 kDa type II transmembrane glycoprotein that has been shown to be 
prognostic in CLL (Damle et al. 1999;Ghia et al. 2003;Hamblin et al. 2002;Huttmann 
et al. 2006). There has been controversy over the use of CD38 as a prognostic marker 
as there is no universally-agreed threshold to classify a patient as CD38 positive, and 
there is also some debate about whether CD38 expression changes over the course of 
the disease (or after treatment) or remains constant. The aim of this study was to 
address these issues and to elucidate a biological rationale for the association between 
CD38 expression and poor prognosis in CLL.
As an initial step, we investigated the relative prognostic capacity of the three 
thresholds previously published by other groups (7%, 20% and 30%) (Damle et al 
1999;Ibrahim et al. 2001;Krober et al. 2002). In agreement with Ibrahim et al ( 2001) 
and other groups (Durig et al. 2002) the 20% threshold was found to be the most 
prognostic as evidenced by the most significant difference in overall survival (OS) 
between the CD38+ and CD38' patients. There was also significant difference in PFS, 
TTFT and OS between the CD38+ and CD38' patients at both the 7% and 30% level, 
but the 20% showed the greatest significant difference. An explanation for the 
improved prognostic power of the 20% threshold level may lie in the fact that a 
significant number of the patients in our cohort had CD38 expression between 20 and 
30% and these patients predominantly had active/progressive disease and poor clinical 
outcomes. Therefore, the 30% threshold appears to exclude a significant number of 
patients with active/progressive disease. In contrast, the 7% threshold appears to 
include a significant number of patients that have stable disease with relatively long
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TTFT and OS. Therefore, the intermediate threshold of 20% represents a good 
compromise resulting in the inclusion of most of the patients with poor outcome 
disease whilst excluding more of the patients with good outcome disease.
Although </>20% CD38 expression proved to be the best threshold for defining 
prognosis in the patient cohort, in agreement with Ghia et al (Ghia et al 2003) the 
expression of the CD38 antigen per se was associated with poor prognosis. This was 
demonstrated by CD38+ patients having significantly shorter PFS, TTFT and OS in 
CD38+ patients. In addition, CD38 expression was associated with other poor clinical 
and prognostic markers such as Binet stage B/C, a LDT >12 months, 17p-/llq- 
/complex cytogenetics, unmutated Vh gene mutation status and ZAP-70 expression.
In agreement with Ghia et al ( 2003) (and disagreement with Hamblin et al ( 2002) 
CD38 expression was found not to change significantly over time which would 
support the use of CD38 as a prospective prognostic marker. When used in 
conjunction with Vh gene mutation status it was found to split the mutated and 
unmutated groups into two groups (giving four in total). Importantly, the combination 
of CD38 expression and Vh gene mutational status identified a subset of patients with 
a poorer prognosis i.e. CD38+/mutated Vh genes. Vh gene mutation status retained its 
superior prognostic power as patients with mutated Vh genes still had a significantly 
better prognosis than patients with unmutated Vh genes irrespective of their CD38 
expression. However, our data suggest that the combination of Vh gene mutation 
status and CD38 expression, and possibly other prognostic markers like ZAP-70, 
might provide added value in terms of more accurately defining the prognosis of
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individual CLL patients. Indeed, a number of groups have already published work to 
this effect (Bilous et al. 2005;Jelinek et al. 2001;Pepper et al. 2007).
Once CD38 expression was shown to be prognostic the next step was to investigate 
the biological rationale behind the association between CD38 expression and poor 
prognosis. In order to explore this, we took advantage of the fact that a proportion of 
CLL patients have bimodal expression of CD38 i.e. they possess distinct subsets of 
CLL cells that are CD38+ and CD38'. By using high speed cell sorting we were able 
to purify these sub-populations derived from the same patient and examine then- 
biological characteristics. As a first step, we demonstrated that these CD38+ and 
CD38' lymphocytes had the same light chain restriction (were monotypic) and had 
essentially the same Vh gene sequence (were monoclonal). Therefore, we could 
conclude that these cellular sub-populations both originated from a single malignant 
transforming event. This data agreed with the findings of Ghia et al ( 2003).
Subsequently, we went on to examine the gene expression signatures of these sub­
populations in order to determine whether we could derive any clues about the poor 
prognosis of CD3 8-expressing CLL patients. CD38+ sub-populations were shown to 
have significantly different gene expression profile to CD38' sub-populations derived 
from the same patient with 61 genes being differentially expressed between these two 
sub- populations when using a two-fold cut-off to define gene expression changes.
Analysis of the gene list revealed two distinct nodes of genes that appeared to be 
associated with one another. One of these nodes was centred around vascular 
endothelial growth factor (VEGF). VEGF was consistently over-expressed in CD38+
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CLL cells when compared to their CD38' counter-parts. Given that a number of 
papers had previously suggested that VEGF might be important in CLL (Ferrajoli et 
al. 2001; McCabe et al 2004) and that there appears to be an association between 
VEGF and CD38 expression, we investigated this further in our purified sub-clonal 
populations. VEGF protein was shown to be relatively over expressed in CD38+ CLL 
cells thereby confirming the transcription data. Furthermore, VEGF expression was 
associated with in vitro survival and the addition of exogenous VEGF caused an 
increase in the anti-apoptotic protein Mcl-1, a downstream effector of VEGF 
signalling. VEGF signalling was significantly inhibited by SU1498 (a VEGF kinase 
inhibitor) but was essentially unaffected by blocking VEGF receptor binding by using 
a VEGFR2 antibody. This data along with the exogenous VEGF data suggests that 
CD38+ sub-populations signal predominantly via an autocrine signalling pathway and 
CD38' sub-populations signal via a paracrine survival loop. In the case of bimodal 
patients the CD38+ sub-populations provide exogenous VEGF which the CD38' sub­
populations can use to signal (Pepper et al 2007).
VEGF signalling through VEGFR2 has been shown to utilise the PI3K/Akt survival 
pathway (Bairey et al. 2004). In this regard, Akt was found to be relatively over 
expressed, in this study both transcriptionally and at the protein level, in the CD38+ 
sub-populations when compared to their CD38" counter-parts. Although it is tempting 
to consider this to be an explanation for why CD38+ sub-populations survive longer 
than the CD38' sub-populations in in vitro culture, the relative increase in PI3K 
activation in CD38+ CLL cells appears not to be mediated via VEGFR2 signalling. 
Interestingly, expression of the down stream effector molecule of the Akt signalling 
pathway, p-S6, was not significantly different between the two sub-populations
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suggesting that survival via this pathway was not significant between CD38+ and 
CD38' sub-populations. Ringshausen et al ( 2002) found that protein kinase C (PKC) 
was important in the survival of CLL suggesting that PKC activation is possibly a 
more important downstream effector of the Akt pathway in CLL cells. Alternatively, 
investigations in our laboratory have found that the transcription factor NF-kB is 
differentially expressed between CD38+ and CD38‘ patients. Previous work by Cuni 
et al ( 2004) found that Akt was an upstream signalling molecule of NF-kB and so 
this molecule may be the important effector of Akt signalling in the CD38+ and CD38' 
sub-populations. Further investigations are currently on-going to try to elucidate the 
relative importance of these molecules in the maintenance of CLL cells.
As CD38+ sub-populations are less susceptible to spontaneous apoptosis than their 
CD38' counter-parts, the next step was to investigate whether CD38+ sub-populations 
were more resistant to chemotherapeutic agents than CD38' sub-populations. 
Somewhat surprisingly, in the majority of patient samples tested (20/25) both sub- 
clonal populations had similar sensitivity to the chemotherapeutic drug fludarabine. 
This indicates that CD38+ CLL cells are not intrinsically more drug resistant when 
compared to their CD38' counter-parts. However, 5/25 patient samples derived from 
patients who had previously received a number of treatment regimens showed marked 
and differential drug resistance in their CD38+ sub-populations. This suggests that 
these cells are preferentially undergoing clonal evolution and a longitudinal analysis 
of the cytogenetics of these sub-populations is currently being conducted in our 
laboratory.
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Although there was differential expression of the apoptotic proteins Bcl-2, Bax and 
Mcl-1 between CD38+ sub-populations and CD38' sub-populations there was no 
significant difference between the Bcl-2/Bax and Mcl-1/Bax ratios in these two sub­
populations. This may help to explain why both the CD38+ and CD38' sub­
populations had similar sensitivity to drug therapeutics.
The flow cytometry methods used throughout this investigation are not without their 
limitations. For instance, the background staining of the isotype-matched control 
antibodies in cells that have been fixed and permeabilised is almost always higher 
than that found for surface antigen isotype controls. This suggests that the fixation and 
permeabilisation process promotes none-specific binding of the antibodies. However, 
it should be noted that the majority of the analyses performed in this study were of 
paired data i.e. CD38+ and CD38' CLL cells derived from the same patient. As such, 
it is reasonable to consider that the level of background, none-specific, binding will be 
the same for each paired set of samples thereby diminishing the chance of measured 
differences in fluorescence intensity being due to artefact. Also as CD38 expression is 
associated with cellular activation, differences in antigen expression between CD38+ 
and CD38' CLL cells measured by flow cytometry may, at least in part, be a reflection 
of the change in cell size. In this context, it has previously been reported that CD38- 
expressing CLL cells are larger than the cells that do not express CD38 (Manocha et 
al. 2003). Despite these caveats, given that the data obtained by flow cytometry was 
also confirmed by Western Blotting techniques it seems highly likely that the 
conclusions reached in this study are justified.
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Taken together, this work for the first time provides a biological rationale for why 
CD38 expression is associated with poor prognosis in CLL. The gene expression 
signatures derived from CD38+ and CD38' sub-populations not only shed new light on 
the biology of these sub-populations of CLL cells but also highlight VEGF and Akt as 
potential therapeutic targets. In addition, the combination of Vh gene mutation status 
and CD38 expression was shown to provide beneficial information about the clinical 
outcome of individual CLL patients.
Possible future work
• Investigate the other genes that were found to be differentially expressed 
between CD38+ and CD38‘ sub-populations derived from the same patient
• Perform knock-down experiments in which CD38 expression is inhibited 
using antisense or SiRNA in order to establish whether a CD38' gene signature 
can be induced in cells that formerly expressed CD38. This would address the 
question of whether CD38 is merely a marker of CLL cell activation.
• knock-in experiments where CD38 would be induced using gene transfer 
techniques
• Perform knock-down experiments in which VEGF expression is inhibited 
using antisense or SiRNA in order to assertain the importance of VEGF to 
CLL cell survival
• Investigate the effect of treatment on the expression levels of Bcl-2, Bax and 
Mcl-1 in CD38+ and CD38" sub-populations.
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